

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA  
CLARKSBURG DIVISION

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

Case No. 1:22-cv-00061-TSK

MYLAN PHARMACEUTICALS INC.,

Defendant.

---

**MEMORANDUM OF LAW IN SUPPORT OF NONPARTY AMGEN INC.'S MOTION  
TO INTERVENE FOR THE LIMITED PURPOSE OF ASSERTING THE PUBLIC  
INTEREST IN ACCESS TO JUDICIAL RECORDS**

---

Nonparty Amgen Inc. (“Movant”), by and through its undersigned counsel, hereby submits this Memorandum in Support of its “Motion to Intervene for the Limited Purpose of Asserting the Public Interest in Access to Judicial Records,” and seeks to intervene in this action pursuant to Fed. R. Civ. P. 24(b) for the limited purpose of unsealing certain judicial records (or portions thereof) currently unavailable to the public, in accordance with the public’s First Amendment and common law rights. In support of this Motion, the Movant states as follows:

**INTRODUCTION**

**I. The Parties**

Plaintiff Regeneron Pharmaceuticals, Inc. (“Regeneron”) developed and sells Eylea® (aflibercept) – a treatment for certain eye diseases. Defendant Mylan Pharmaceuticals Inc. (“Mylan”) is seeking FDA approval under the Biologics Price Competition and Innovation Act (“BPCIA”), 42 U.S.C. §§ 262(k)-(l), to commercialize “M710,” a proposed biosimilar of Eylea. Regeneron initiated this action (“Action”) seeking a judgment of patent infringement against Mylan to prevent M710 from coming to market and competing with Eylea. On April 20, 2023, the

parties filed motions for summary judgment. A 10-day bench trial is scheduled to begin on June 12, 2023.

## **II. The Movant**

Movant, one of the world's leading biopharmaceutical companies, is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320. Movant's biosimilar business is committed to building on Amgen's experience in the development, manufacture, and distribution of biological medicines.

Movant has devoted considerable effort to developing a proposed biosimilar of Eylea, which is currently designated "ABP 938." For example, Movant has completed the primary analysis of a randomized, double-blind, active controlled Phase III study evaluating the efficacy and safety of ABP 938 compared with Eylea. The final analysis is expected to be completed by June 2023.

## **III. The Parties' Sealing Practices**

During the course of the Action, the parties have filed numerous documents under seal. But, for the most part, the docket sheet does not list motions to seal with titles explaining what documents the party seeks to seal and the public cannot access the actual motions or pleadings: the motion and number where those pleadings or motions should be listed are absent from the docket sheet.<sup>1</sup> For example, ECF Nos. 106, 119, 122, 133, 135, 146, 173, 174, 226, 228, 246, 261, 286, 301, 305, 307, 309, 311, 313, 314, 322, 324, 335, 336, 337, 339, 342, 352, 353, 356, 357, 360, 375, 377, 389, 391, 392, 403, 410, 430, 440, 441, 443, 445, 448, 449, 454, 455, 463, 466, 467, 469, 470, 471, 472, 473, 474, 476, 477, 478, 479, 480 and 482 have been omitted from the

---

<sup>1</sup> The docket sheet for this Action is attached as Exhibit A.

docket sheet. The only place some of these submissions can be found is in the descriptions of orders granting various motions to seal. *See* ECF at Nos. 132, 134, 136, 185, 186, 227, 251, 263, 308, 310, 312, 334, 336, 338, 355, 359, 390, 405, 409, 411 and 464. Other orders state “SEALED,” but do not identify in the description what is being sealed or what motion is being granted. *See* ECF at Nos. 297, 298, 351, 361, 368, 376, 431, 442, 444, 462, 465 and 468. Moreover, each order granting the numerous motions to seal is itself sealed. Consequently, in general, no determination can be made as to what was sealed or the justification for sealing it.

The docket sheet does identify a few documents that the parties requested to be sealed or that were sealed:

- Regeneron requested that subpoenas to third-parties that supplied materials to Mylan be sealed. *See* ECF at Nos. 107, 120.
- Mylan requested that its Opening Claim Construction Brief be sealed. *See* ECF at No. 123.
- Mylan’s Responsive Claim Construction Brief, and the exhibits attached thereto, were sealed in their entirety. *See* ECF at No. 187.
- Regeneron’s Responsive Claim Construction Brief, and the exhibits attached thereto, were sealed in their entirety. *See* ECF at No. 188.
- Mylan’s Response in Opposition to Regeneron’s Motion for Judgment on the Pleadings as to Mylan’s Inequitable Conduct Defenses and Counterclaims and the exhibits attached thereto were sealed in their entirety. *See* ECF at No. 252.
- Mylan’s Motion to Strike Plaintiff’s Unauthorized Reply Brief on Claim Construction Issues or, Alternatively, for Leave to File Response, and the exhibits attached thereto, were sealed in their entirety. *See* ECF at No. 264.
- Regeneron’s Motion for Presumption Under 35 U.S.C. § 295 and the exhibits attached thereto, were sealed in their entirety. *See* ECF at No. 299.<sup>2</sup>
- Mylan’s Memorandum in support of its motion for summary judgment, and the exhibits attached thereto, were sealed in their entirety. *See* ECF at No. 429.

But no order justifying sealing these documents is available for review. Moreover, the parties have not filed redacted versions of these documents in the public record.

---

<sup>2</sup> On May 12, 2023, pursuant to Regeneron’s Motion (ECF 438), the Court denied Regeneron’s Motion for Presumption as moot. *See* ECF 456. Nonetheless, Regeneron’s Motion for Presumption and the exhibits attached thereto remain sealed.

## ARGUMENT

### I. Movant's Limited Intervention is Proper Under Fed. R. Civ. P. 24(b)

The Court should permit Movant to intervene in this action to assert the public's right of access to these judicial proceedings. Permissive intervention under Fed. R. Civ. P. 24(b) is the appropriate method for a nonparty to assert the public's right to access to judicial proceedings and seek access to protected or sealed documents. *See In re Grand Jury Subpoena*, 836 F.2d 1468, 1470 (4th Cir. 1988); *Kirby v. Res-Care, Inc.*, 596 F. Supp. 3d 588, 592 (S.D.W. Va. 2022) (“[P]ermissive intervention is an appropriate method for a nonparty to seek access to protected or sealed documents.”); *see also Grove Fresh Distributors, Inc. v. Everfresh Juice Co.*, 24 F.3d 893, 896 (7th Cir. 1994) (“[I]ntervention is the procedurally appropriate course for third-party challenges to protective orders.”).

“It is well settled that the public and press have a qualified right of access to [judicial documents and records] filed in civil and criminal proceedings.” *Doe v. Public Citizen*, 749 F.3d 246, 265 (4th Cir. 2014). Consistent with that well-settled principle, the Fourth Circuit has held that “the press has standing to intervene in actions in which it is not otherwise a party to seek review of a district court’s order sealing documents and court records.” *Rosenfeld v. Montgomery Cty. Public Schs.*, 25 F.App’x 123, 131 (4th Cir. 2011); *see also Stone v. Univ of Md. Med. Sys. Corp.*, 855 F.2d 178, 180-181 (4th Cir. 1988); *Virginia Dep’t of State Police v. Washington Post*, 386 F.3d 567, 572 (4th Cir. 2004).

The public’s standing to intervene is no different than that of the media. *Doe*, 749 F.3d at 263 (“We see no reason why the standing of news media to seek appellate review of a district court’s sealing order should differ from that of a member of the general public.”); *see also In re Greensboro News Co.*, 727 F.2d 1320, 1322 (4th Cir. 1984) (holding that the rights of access of the media “are co-extensive with and do not exceed those rights of members of the public in general”).

As explained by the Seventh Circuit, “every court of appeals to consider the matter has come to the conclusion that Rule 24 is sufficiently broad-gauged to support a request for intervention for the purposes of challenging confidential orders.” *Jessup v. Luther*, 227 F.3d 993, 997 (7th Cir. 2000); *see also Phenix Newspapers, Inc. v. U.S. Dist. Ct.*, 156 F.3d 940, 949 (9th Cir. 1998) (finding that it is well-established that nonparties have standing to intervene to gain public access to sealed court documents). The First Amendment’s protections to judicial documents would be meaningless without the ability for nonparties to intervene to seek access to withheld documents. *See CBS Inc. v. Young*, 522 F.2d 234, 237-38 (6th Cir. 1975). Movant has standing to intervene as a member of the public.

Movant’s motion for limited intervention is timely and will not unduly delay or prejudice the adjudication of the merits. Movant does not seek to adjust the case schedule or to participate in any aspect of the Action. Because access to judicial proceedings remains relevant even after a case ends, there is no particular time limit for a party to intervene for the limited purpose of seeking access to judicial proceedings. Courts, including the Third Circuit, “have allowed intervention by parties for the limited purpose of modifying a confidentiality or protective order even after the underlying dispute between the parties has been settled.” *Pansy v. Borough of Stroudsburg*, 23 F.3d 772, 779 (3d Cir. 1994); *Kirby*, 596 F. Supp. at 592 (finding that intervention for the purpose of asserting the right of access “can be appropriate even after entry of a final judgment”). By seeking to litigate only an issue of access under the protective order, Movant would not disrupt this case on the merits. *Pansy*, 23 F.3d at 780.

For these reasons, Movant should be permitted to intervene under Rule 24(b).

## **II. The Extensive Sealing in This Action Is Inconsistent with the Public’s Common Law and First Amendment Rights of Access to Courts**

---

“It is clear that the courts of this country recognize a general right to inspect and copy public records and documents.” *Nixon v. Warner Commc’ns, Inc.*, 435 U.S. 589, 597 (1978). “[D]ocuments filed with the court are ‘judicial records’ if they play a role in the adjudicative process, or adjudicate substantive rights.” *In re Application of U.S. for an Order Pursuant to 18 U.S.C. Section 2703(d)*, 707 F.3d 283, 290 (4th Cir. 2013). Stated differently, documents filed with the objective of obtaining judicial action or relief constitute judicial records. *Id.* at 291. Of course, judicial orders constitute judicial records. *Id.* at 290. Pursuant to Local Rule of Civil Procedure 26.05(b), “[t]he rule requiring public inspection of Court documents is necessary to allow interested parties to judge the Court’s work product in the cases assigned to it.” N.D. W.Va. LR Civ. P. 26.05(b); *see also Columbus-America Discovery Group v. Atlantic Mut. Ins. Co.*, 203 F.3d 291, 303 (4th Cir. 2000).

This right of public access to documents or materials filed in a district court is derived from two independent sources: the common law and the First Amendment. *Virginia Dep’t of State Police*, 386 F.3d at 575. “While the common law presumption in favor of access attaches to all judicial records and documents, the First Amendment guarantee of access has been extended to particular judicial records and documents.” *Stone*, 855 F.2d at 180. The First Amendment right of access to judicial records attaches if: “(1) ‘the place and process have historically been open to the press and general public’ and (2) ‘public access plays a significant positive role in the functioning of the particular process in question.’” *Harper v. Elk Run Coal Co.*, 2012 WL 1999429, at \*4 (S.D. W.Va. June 12, 2012) (quoting *Press-Enterprises Co. v. Superior Court*, 478 U.S. 1, 8-9 (1986)). The Fourth Circuit has specifically found that the public’s access to motions

for summary judgment and documents attached thereto is protected by the First Amendment. *Rushford v. New Yorker Magazine, Inc.*, 846 F.2d 249, 253 (4th Cir. 1988).

For judicial records that are subject to First Amendment protections, there is a higher bar for restricting the public's right of access. *Virginia Dep't of State Police*, 386 F.3d at 575. A district court may restrict the First Amendment right “only on the basis of a compelling governmental interest, and only if the denial is narrowly tailored to serve that interest.” *Id.* (quoting *Stone*, 855 F.2d at 180). The party seeking to restrict access to judicial records bears the substantial burden of overcoming the First Amendment's protections by presenting specific reasons in support of their position. Conclusory assertions are insufficient to meet this burden. *Virginia Dep't of State Police*, 386 F.3d at 575.

In addressing the common law right of access, District Judge Gina M. Groh explained:

The common law right of access applies to all judicial records that do not fall under the First Amendment's protection. *Id.* at 576. The common law “presumption of access, however, can be rebutted if countervailing interests heavily outweigh the public interest in access, and [t]he party seeking to overcome the presumption bears the burden of showing some significant interest that outweighs the presumption.” *Id.* at 575 (quotation marks and citation omitted). The following factors are relevant to this balancing test: (1) “whether the records are sought for improper purposes, such as promoting public scandals or unfairly gaining a business advantage;” (2) “whether release would enhance the public's understanding of an important historical event; and” (3) “whether the public already has access to the information contained in the records.”” *Id.* (quotation marks and citation omitted). It is within the district court's discretion to decide whether to restrict the common law right of access. *See id.* The court should, however, exercise this discretion in light of the case's “relevant facts and circumstances.” *Id.* (quotation marks and citation omitted).

*Patrick v. PHH Mortg. Corp.*, 2014 U.S. Dist. LEXIS 190143 (N.D. W.Va. Apr. 30, 2014).

Whether access to a judicial record is subject to the protections of the First Amendment or simply the common law, said access “may be abrogated only in unusual circumstances.” *Stone*, 855 F.2d at 182; *see also* N.D. W.Va. LR Civ. P. 26.05(b) (stating that the rule requiring public access to judicial records “may be abrogated only in exceptional circumstances”). A district court considering a motion to seal must initially determine, as to each document, whether the judicial record is subject to First Amendment or the common law protections. *Stone*, 855, F.2d at 181 (“The district court in this case ordered sealed the entire record without indicating exactly what that record contained. On remand, it must determine the source of the right of access with respect to each document sealed. Only then can it accurately weigh the competing interests at stake.”). Once the district court has ascertained the applicable standard to weigh competing interests, it must then weigh those interests in accordance with the following procedures:

First, the district court must give the public adequate notice that the sealing of documents may be ordered. *In re Knight Publishing Co.*, 743 F.2d at 234. Second, the district court must provide interested persons “an opportunity to object to the request before the court ma[kes] its decision.” *Id.* at 235. Third, if the district court decides to close a hearing or seal documents, “it must state its reasons on the record, supported by specific findings.” *Id.* at 234. Finally, the court must state its reasons for rejecting alternatives to closure. *Id.* at 235.

*Rushford*, 846 F.2d at 253-254 (internal citations omitted) (quoting *In re Knight Publishing Co.*, 743 F.2d 231, 234-235 (4th Cir. 1984)).

**A. The Public Was Not Given Adequate Notice Or An Opportunity To Object**

Before a document is sealed, the public must be given notice and an opportunity to object to the sealing of a judicial record. *Media Gen. Operations, Inc. v. Buchanan*, 417 S.E.2d 424, 429 (4th Cir. 2005). The notice requirement may be met by placing a motion to seal on the docket



sheet<sup>3</sup>; however, notice must be given “reasonably in advance of deciding the issue.” *Knight Publishing Co.*, 743 S.E.2d at 235. In fact, the public has a First Amendment right to a civil action’s docket sheet. *Doe*, 749 F.3d at 270. In the instant action, no notice was given as to the various motions to seal filed. The motions are not identified on the docket sheet. In fact, not only is there no description of a motion to seal located on the docket sheet, the numbers under which the motions should be listed are omitted. *See* ECF at Nos. 106, 119, 122, 133, 135, 146, 173, 174, 226, 228, 246, 261, 286, 301, 305, 307, 309, 311, 313, 314, 322, 324, 335, 336, 337, 339, 342, 352, 353, 356, 357, 360, 375, 377, 389, 391, 392, 403, 410, 430, 440, 441, 443, 445, 448, 449, 454, 455, 463, 466, 467, 469, 470, 471, 472, 473, 474, 476, 477, 478, 479, 480 and 482 . Some of the numbers for the unlisted motions can be found in the order granting the motion to seal; however, there is still no title given to the motion or description of what is being sealed. *See* ECF at Nos. 132, 134, 136, 185, 186, 227, 251, 263, 308, 310, 312, 334, 336, 338, 355, 359, 390, 405, 409, 411 and 464. Of course, by the time an order granting the motion to seal appears on the docket, there is no opportunity to object before the issue is decided. Other motions to seal appear to have been granted without ever being identified beforehand. *See* ECF at Nos. 297, 298, 351, 361, 368, 376, 431, 442, 444, 462, 465 and 468.

As the public was not given proper notice of the numerous motions to seal, the necessary procedural requirements were not met.

**B. The Public Has No Access To Any Order Stating The Reasons For Sealing Judicial Records In This Matter**

The procedure required in *Knight Publishing Co.* dictates that the Court should provide reasons for sealing any documents, including with specific supporting findings. Here, the public,

---

<sup>3</sup> *Patrick*, 2014 U.S. Dist. LEXIS 190143, at \*6.

including Movant, cannot access any of the orders granting the various motions to seal or the facts supporting the Court's rulings. As such, Movant is precluded from analyzing the documents sealed and the appropriateness of each determination.

**C. The Public Received No Explanation As To Why Alternatives To Sealing The Various Documents Were Rejected**

When a court considers a motion to seal judicial records, “a judicial officer ‘must consider alternatives to sealing the documents’ which may include giving the public access to some of the documents or releasing a redacted version of the documents that are the subject of the government’s motion to seal.” *United States v. Appelbaum*, 707 F.3d 283, 294 (4th Cir. 2013) (quoting *Media Gen. Operations, Inc.*, 417 F.3d at 429 (internal citation omitted)); *see also Knight Publishing Co.*, 743 F.2d at 235 (holding that a district court must consider less restrictive alternatives to sealing and, if it elects to seal the document, then it must provide the reasons for rejecting such alternatives); N.D. W.Va. LR Civ. P. 26.05 (“Unless otherwise authorized by law, a motion to seal . . . shall be accompanied by a memorandum which contains . . . the reasons why sealing is necessary, including the reasons why alternatives to sealing, such as redaction, are inadequate . . .”). Again, as there are no orders to review, the public does not know whether alternatives to sealing, such as redaction, were considered and, if so, why they were rejected.

**D. Mere Allegations That Documents Contain Sensitive Business Information Do Not Justify Wholesale Restriction Of Access**

Movant recognizes that the public access to judicial records and proceedings is not absolute and that an exception exists for commercially sensitive business information. *Nixon v. Warner*, 435 U.S. at 598. But a party seeking to restrict access to judicial records bears the burden of establishing that the records do in fact contain commercially sensitive business information. If a party can make that showing, “sealing should be limited to only those portions necessary to prevent the disclosure of [sensitive business information].” *Lifenet Health v. Lifecell Corp.*, 2015 U.S.

Dist. LEXIS 181315, at \*4 (S.D. W.Va. Jan. 9, 2015) (quoting *Woven Elecs. Corp. v. Advance Group, Inc.*, 1991 U.S. App. LEXIS 14345, at \*6 (4th Cir. Apr. 15, 1991)). “Such a partial sealing strikes an appropriate balance between the public’s right of access to judicial records and proceedings and the parties’ legitimate interest in the protection of sensitive proprietary information.” *Lifenet Health*, 2015 U.S. Dist. LEXIS 181315, at \*5 (quoting *Woven Elecs. Corp.*, 1991 U.S. App. LEXIS 14345, at \*6). Blanket sealing of the record is not appropriate. *Lifenet Health*, 2015 U.S. Dist. LEXIS 181315, at \*4. Failure to narrowly tailor one’s motion to seal so that it solely protects commercially sensitive business information should result in the denial of the motion to seal. *Id.* at \*6.

Movant assumes that Regeneron and Mylan will argue that at least some of the sealed documents contain commercially sensitive business information. To be clear, Movant does not seek access to Regeneron’s or Mylan’s commercially sensitive business information. But the public record does not demonstrate that the documents sealed by the Court at the request of Regeneron or Mylan contain commercially sensitive business information, or that the restriction imposed, *i.e.*, sealing of the documents, was narrowly tailored so that only such information is protected.

**E. A Protective Order Does Not Shield Parties From Complying With The Fourth Circuit’s Sealing Requirements**

The Parties stipulated to a protective order that the Court entered on November 2, 2022. ECF at No. 91. Nonetheless, the Parties and Court are still obligated to comply with the Fourth Circuit’s sealing requirements as set forth herein. *In re C.R. Bard, Inc. Pelevic Repair System Prods. Liab. Litig.*, 2013 U.S. LEXIS 70189, at \*21 (S.D. W.Va. May 17, 2013) (holding that even when the parties agree to the proposed redactions, the court is still required to assure that First Amendment protections to the right to access are properly weighed and considered); *see also Trs.*

*of Purdue Univ. v. Wolfspeed, Inc.*, 2023 U.S. Dist. LEXIS 60521, at \*10 (M.D.N.C. Feb. 28, 2023).

That the parties have entered into a protective order and redacted or sealed a document in accordance therewith thus does not relieve the parties or the Court from complying with the process for sealing documents set forth in *In re Knight Publishing Co.*

**F. The Court Should At Least Unseal All Motions For Summary Judgment and Supporting Briefs and Exhibits; Claim Construction Briefs and Exhibits; and Any Other Dispositive Motions and Supporting Briefs and Exhibits**

Access to dispositive motions, including motions for summary judgment and related briefs and documents attached thereto, are protected by the public's First Amendment right to access judicial records. *Rushford*, 846 F.2d at 253. Consequently, only a compelling government interest can warrant sealing these materials, and even if warranted, sealing must be narrowly tailored to serve the compelling interest. *Virginia Dep't of State Police*, 386 F.3d at 575.

Mylan filed a motion for summary judgment on April 20, 2023, with respect to four Regeneron patents. *See* ECF at No. 429. Although no motion to seal or order to seal can be found on the docket sheet, the motion says that Mylan filed a supporting memorandum under seal. *Id.* Shortly after Mylan filed its motion, Regeneron stipulated to summary judgment against it for certain claims of certain patents. *See* ECF at No. 433. Mylan's summary judgment brief and exhibits should be in the public record to afford the public access to a motion that led to resolution of certain claims in the case.

Likewise, any briefs concerning claim construction should be in the public record to afford the public access to the arguments the parties advanced concerning claim construction. The resolution of claim construction issues also led, in part, to Regeneron's agreement to stipulate to summary judgment for certain claims. *See* ECF at No. 433 (stipulating to summary judgment "under the Court's Claim Construction").

Further, Mylan's Answer, Defenses, and Counterclaims to Plaintiff's Complaint includes allegations that certain Regeneron patents are unenforceable due to Regeneron's inequitable conduct during prosecution before the U.S. Patent Office. *See* ECF at No. 47. On December 16, 2022, Regeneron filed a motion for judgment on the pleadings as to these inequitable conduct defenses and counterclaims. *See* ECF at No. 175. While the patent prosecution records are publicly available, Mylan's responsive brief and supporting exhibits were sealed in their entirety. *See* ECF at No. 252. These materials should be unsealed, or at least a redacted version should be filed, to afford the public access to these potentially dispositive allegations.

### **III. Requested Actions**

Movant respectfully requests that the Court take the following actions:

- i. Order that all summary judgment, claim construction, and inequitable conduct motions, briefs, and exhibits be filed in the public record, or that the parties file redacted versions of all such materials with redactions limited to information for which a compelling interest warrants sealing.
- ii. Add all previously filed motions to seal to the public docket sheet.
- iii. Add all previously filed sealing orders to the public docket sheet.
- iv. Review the current extent of sealing in light of the First Amendment and common law rights of the public. If the Court decides that the parties' motions to seal do not satisfy the Fourth Circuit's requirements for sealing, in whole or in part, the sealing requests should be denied, and the filings (or the appropriate portions thereof) should be made available to the public. If the Court decides that the parties' motions to seal satisfy the Fourth Circuit's requirements for sealing, in whole or in part, Movant respectfully requests that the Court provide public access to the reasons for sealing, including why alternatives to sealing, such as redaction, are inadequate.
- v. Require the parties to file motions to seal any additional filings that they seek to seal, in whole or in part.
- vi. Ensure that the public has in-person and/or remote access to the trial in the Action, and any associated hearings, exhibits, and testimony, except to the extent a party establishes entitlement to seal portions to protect commercially sensitive business information.

**CONCLUSION**

For the aforesaid reasons, Nonparty Amgen Inc., respectfully requests that the Court grant this Motion to Intervene and take the requested actions set forth above.

**DATED:** May 23, 2023

**AMGEN INC.**

By: Hendrickson & Long, PLLC

/s/ John H. Tinney  
John H. Tinney, Jr. (Bar No. 6970)  
John K. Cecil (Bar No. 9511)  
HENDRICKSON & LONG, PLLC  
214 Capital Street  
Charleston, West Virginia 25301  
(304) 346-5500  
[jtinney@handl.com](mailto:jtinney@handl.com)  
[jcecil@handl.com](mailto:jcecil@handl.com)

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA  
CLARKSBURG DIVISION

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

Case No. 1:22-cv-00061-TSK

MYLAN PHARMACEUTICALS INC.,

Defendant.

**CERTIFICATE OF SERVICE**

I hereby certify that on this 23<sup>rd</sup> day of May, 2023, a copy of the foregoing pleading was filed with the Clerk of the Court using the CM/ECF system. Notice of this filing will be sent by operation of the Court's electronic filing system to all parties registered to receive electronic notice.

/s/ John H. Tinney  
John H. Tinney, Jr. (Bar No. 6970)  
John K. Cecil (Bar No. 9511)  
HENDRICKSON & LONG, PLLC  
214 Capital Street  
Charleston, West Virginia 25301  
(304) 346-5500  
[jtinney@handl.com](mailto:jtinney@handl.com)  
[jcecil@handl.com](mailto:jcecil@handl.com)

**EXHIBIT A**



**U.S. District Court**  
**Northern District of West Virginia (Clarksburg)**  
**CIVIL DOCKET FOR CASE #: 1:22-cv-00061-TSK-JPM**

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.  
Assigned to: Chief District Judge Thomas S Kleeh  
Referred to: Magistrate Judge James P. Mazzone  
Cause: 28:1338 Patent Infringement

Date Filed: 08/02/2022  
Jury Demand: Plaintiff  
Nature of Suit: 830 Patent  
Jurisdiction: Federal Question

**Plaintiff**

**Regeneron Pharmaceuticals, Inc.**

represented by **Adam J. Bernstein**  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591-6717  
(914) 847-8042  
Email: adam.bernstein@regeneron.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Adam Pan**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: apan@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Andrew E. Goldsmith**  
Kellogg, Hansen, Todd, Figel & Frederick,  
P.L.L.C.  
1615 M Street NW  
Suite 400  
Washington, DC 20036  
(202) 326-7945  
Fax: (202) 326-7999  
Email: agoldsmith@kellogghansen.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Andrew V. Trask**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: atrask@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Arthur J. Argall, III**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Fax: (202) 434-5029  
Email: aargall@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Arunabha Bhoumik**  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591-6717  
(914) 847-3713  
Email: arunabha.bhoumik@regeneron.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**David I. Berl**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: dberl@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**David R. Pogue**  
Carey, Douglas, Kessler & Ruby, PLLC  
707 Virginia Street, East  
Suite 901  
Charleston, WV 25301  
((304) 345-1234  
Fax: (304) 342-1105  
Email: drpogue@cdkrlaw.com  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Ellen E. Oberwetter**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: eoberwetter@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Evan T. Leo**

Kellogg, Hansen, Todd, Figel & Frederick,  
P.L.L.C.  
1615 M Street NW  
Suite 400  
Washington, DC 20036  
(202) 326-7930  
Fax: (202) 326-7999  
Email: [eleo@kellogghansen.com](mailto:eleo@kellogghansen.com)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Grace W. Knofczynski**  
Kellogg, Hansen, Todd, Figel & Frederick,  
P.L.L.C.  
1615 M Street NW  
Suite 400  
Washington, DC 20036  
(202) 326-7900  
Fax: (202) 326-7999  
Email: [gknofczynski@kellogghansen.com](mailto:gknofczynski@kellogghansen.com)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Haylee Bernal Anderson**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Fax: (202) 434-5029  
Email: [handerson@wc.com](mailto:handerson@wc.com)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Jacob E. Hartman**  
Kellogg, Hansen, Todd, Figel & Frederick,  
P.L.L.C.  
1615 M Street NW  
Suite 400  
Washington, DC 20036  
(202) 326-7989  
Fax: (202) 326-7999  
Email: [jhartman@kellogghansen.com](mailto:jhartman@kellogghansen.com)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**James Evans**  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591-6717  
(914) 847-3974

Email: james.evans@regeneron.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Kathryn S. Kayali**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: kkayali@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Larry Coury**  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591-6717  
(914) 847-3625  
Email: larry.coury@regeneron.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Mary Charlotte Y. Carroll**  
Kellogg, Hansen, Todd, Figel & Frederick,  
P.L.L.C.  
1615 M Street NW  
Suite 400  
Washington, DC 20036  
(202) 326-7932  
Fax: (202) 326-7999  
Email: mcarroll@kellogghansen.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Nicholas Jordan**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: njordan@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Petra Scamborova**  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591-6717  
(914) 847-7611  
Email: petra.scamborova@regeneron.com

*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Raymond S Franks , II**  
Carey, Douglas, Kessler & Ruby, PLLC  
707 Virginia Street, East  
Suite 901  
Charleston, WV 25301  
304-345-1234  
Fax: 304-342-1105  
Email: rfranks@cdkrlaw.com  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Rebecca A. Carter**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Fax: (202) 434-5029  
Email: rebeccacarter@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Renee M. Griffin**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5627  
Fax: (202) 434-5029  
Email: rgriffin@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Sean M. Douglass**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Fax: (202) 434-5029  
Email: sdouglass@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Shaun P. Mahaffy**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Fax: (202) 434-5029

Email: smahaffy@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Steven Robert Ruby**  
Carey, Douglas, Kessler & Ruby, PLLC  
707 Virginia Street, East  
Suite 901  
Charleston, WV 25301  
(304) 345-1234  
Fax: (304) 342-1105  
Email: sruby@cdkrlaw.com  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Sven Eric Henningson , III**  
Kellogg, Hansen, Todd, Figel & Frederick,  
P.L.L.C.  
1615 M Street NW  
Suite 400  
Washington, DC 20036  
(202) 367-7805  
Fax: (202) 326-7999  
Email: shenningson@kellogghansen.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Teagan J. Gregory**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: tgregory@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Thomas S. Fletcher**  
Williams & Connolly LLP - Washington  
680 Maine Avenue, SW  
Washington, DC 20024  
(202) 434-5000  
Email: tfletcher@wc.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**S. Benjamin Bryant**  
Carey, Douglas, Kessler & Ruby PLLC  
901 Chase Tower  
707 Virginia Street, East  
Charleston, WV 25301

304-345-1234

Fax: 304-342-1105

Email: sbbryant@cdkrlaw.com

*ATTORNEY TO BE NOTICED*

V.

**Defendant****Mylan Pharmaceuticals Inc.**represented by **Abraham J. Varon**

Rakoczy, Molino, Mazzochi &amp; Siwik, LLP

6 W. Hubbard St.

Suite 500

Chicago, IL 60654

(312) 527-2157

Fax: (312) 843-6260

Email: avaron@rmmslegal.com

*LEAD ATTORNEY**PRO HAC VICE**ATTORNEY TO BE NOTICED***Deanne M. Mazzochi**

Rakoczy, Molino, Mazzochi &amp; Siwik, LLP

6 W. Hubbard St.

Suite 500

Chicago, IL 60654

(312) 527-2157

Fax: (312) 843-6260

Email: dmazzochi@rmmslegal.com

*LEAD ATTORNEY**PRO HAC VICE**ATTORNEY TO BE NOTICED***Eric R. Hunt**

Rakoczy, Molino, Mazzochi &amp; Siwik, LLP

6 W. Hubbard St.

Suite 500

Chicago, IL 60654

(312) 527-2157

Fax: (312) 843-6260

Email: ehunt@rmmslegal.com

*LEAD ATTORNEY**PRO HAC VICE**ATTORNEY TO BE NOTICED***Garrett Matthew Spiker**

Steptoe &amp; Johnson PLLC

400 White Oaks Blvd.

Bridgeport, WV 26330

304-933-8149

Email: garrett.spiker@steptoe-johnson.com

*LEAD ATTORNEY**ATTORNEY TO BE NOTICED*

**Gordon H. Copland**

Steptoe & Johnson PLLC - Bridgeport  
400 White Oaks Blvd  
Bridgeport, WV 26330  
304-933-8162  
Fax: 304-933-8183  
Email: Gordon.Copland@steptoe-johnson.com

*LEAD ATTORNEY*

*ATTORNEY TO BE NOTICED*

**Heinz J. Salmen**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: hsalmen@rmmslegal.com

*LEAD ATTORNEY*

*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**Jake R. Ritthamel**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 222-5101  
Fax: (312) 843-6260  
Email: jritthamel@rmmslegal.com

*LEAD ATTORNEY*

*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**Jeffery A. Marx**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: jmarx@rmmslegal.com

*LEAD ATTORNEY*

*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**John D. Pizzo**

Steptoe & Johnson PLLC - Bridgeport  
400 White Oaks Blvd  
Bridgeport, WV 26330  
(304) 933-8000  
Fax: (304) 933-8183  
Email: john.pizzo@steptoe-johnson.com



*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Katie A. Boda**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: kboda@rmmslegal.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Lauren M. Lesko**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 222-7245  
Fax: (312) 843-6260  
Email: llesko@rmmslegal.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Lawrence Scott Beall**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: sbeall@rmmslegal.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Neil B. McLaughlin**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: nmclaughlin@rmmslegal.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Steven J. Birkos**

Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.

Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: sbirkos@rmmslegal.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Thomas H. Ehrich**  
Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: tehrich@rmmslegal.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**William J O'Brien**  
Steptoe & Johnson PLLC - Bridgeport  
400 White Oaks Blvd  
Bridgeport, WV 26330  
(304) 933-8181  
Fax: (304) 933-8183  
Email: William.Obrien@Steptoe-  
Johnson.com  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**William A. Rakoczy**  
Rakoczy, Molino, Mazzochi & Siwik, LLP  
6 W. Hubbard St.  
Suite 500  
Chicago, IL 60654  
(312) 527-2157  
Fax: (312) 843-6260  
Email: wrakoczy@rmmslegal.com  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Stephene Raychel Gandee**  
Steptoe & Johnson PLLC - Bridgeport  
400 White Oaks Blvd  
Bridgeport, WV 26330  
(304) 933-8126  
Fax: (304) 933-8183  
Email: stephenee.gandee@steptoe-  
johnson.com  
*ATTORNEY TO BE NOTICED*

**Counter Claimant**

**Mylan Pharmaceuticals Inc.**

represented by **Abraham J. Varon**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Deanne M. Mazzochi**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Eric R. Hunt**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Gordon H. Copland**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Heinz J. Salmen**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Jake R. Ritthamel**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Jeffery A. Marx**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Katie A. Boda**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Lauren M. Lesko**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Lawrence Scott Beall**  
(See above for address)  
*LEAD ATTORNEY*

*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Neil B. McLaughlin**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Steven J. Birkos**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Thomas H. Ehrich**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**William J O'Brien**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**William A. Rakoczy**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**John D. Pizzo**  
(See above for address)  
*ATTORNEY TO BE NOTICED*

V.

**Counter Defendant**

**Regeneron Pharmaceuticals, Inc.**

represented by **Adam J. Bernstein**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Adam Pan**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Andrew E. Goldsmith**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Andrew V. Trask**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Arthur J. Argall , III**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Arunabha Bhoumik**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**David I. Berl**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**David R. Pogue**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Ellen E. Oberwetter**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Evan T. Leo**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Grace W. Knofczynski**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Haylee Bernal Anderson**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Jacob E. Hartman**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**James Evans**

(See above for address)

*LEAD ATTORNEY*

*ATTORNEY TO BE NOTICED*

**Kathryn S. Kayali**

(See above for address)

*LEAD ATTORNEY*

*ATTORNEY TO BE NOTICED*

**Larry Coury**

(See above for address)

*LEAD ATTORNEY*

*ATTORNEY TO BE NOTICED*

**Mary Charlotte Y. Carroll**

(See above for address)

*LEAD ATTORNEY*

*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**Nicholas Jordan**

(See above for address)

*LEAD ATTORNEY*

*ATTORNEY TO BE NOTICED*

**Petra Scamborova**

(See above for address)

*LEAD ATTORNEY*

*ATTORNEY TO BE NOTICED*

**Rebecca A. Carter**

(See above for address)

*LEAD ATTORNEY*

*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**Renee M. Griffin**

(See above for address)

*LEAD ATTORNEY*

*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**Sean M. Douglass**

(See above for address)

*LEAD ATTORNEY*

*PRO HAC VICE*

*ATTORNEY TO BE NOTICED*

**Shaun P. Mahaffy**

(See above for address)

*LEAD ATTORNEY*

ATTORNEY TO BE NOTICED

**Steven Robert Ruby**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Sven Eric Henningson , III**  
(See above for address)  
*LEAD ATTORNEY*  
*PRO HAC VICE*  
*ATTORNEY TO BE NOTICED*

**Teagan J. Gregory**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

**Thomas S. Fletcher**  
(See above for address)  
*LEAD ATTORNEY*  
*ATTORNEY TO BE NOTICED*

Date Filed	#	Docket Text
08/02/2022	<a href="#"><u>1</u></a>	COMPLAINT against Mylan Pharmaceuticals Inc., filed by Regeneron Pharmaceuticals, Inc. Filing Fee \$402. Receipt #AWVNDC-3522822. (Attachments: # <a href="#"><u>1</u></a> Exhibit 1 - US Patent 7,070,959 B1, # <a href="#"><u>2</u></a> Exhibit 2 - US Patent 9,222,106 B2, # <a href="#"><u>3</u></a> Exhibit 3 - US Patent 9,254,338 B2, # <a href="#"><u>4</u></a> Exhibit 4 - US Patent 9,669,069 B2, # <a href="#"><u>5</u></a> Exhibit 5 - US Patent 9,816,110 B2, # <a href="#"><u>6</u></a> Exhibit 6 - US Patent 10,130,681 B2, # <a href="#"><u>7</u></a> Exhibit 7 - US Patent 10,406,226 B2, # <a href="#"><u>8</u></a> Exhibit 8 - US Patent 10,415,055 B2, # <a href="#"><u>9</u></a> Exhibit 9 - US Patent 10,464,992 B2, # <a href="#"><u>10</u></a> Exhibit 10 - US Patent 10,669,594 B2, # <a href="#"><u>11</u></a> Exhibit 11 - US Patent 10,857,205 B2, # <a href="#"><u>12</u></a> Exhibit 12 - US Patent 10,888,601 B2, # <a href="#"><u>13</u></a> Exhibit 13 - US Patent 10,927,342 B2, # <a href="#"><u>14</u></a> Exhibit 14 - US Patent 10,973,879 B2, # <a href="#"><u>15</u></a> Exhibit 15 - US Patent 11,053,280 B2, # <a href="#"><u>16</u></a> Exhibit 16 - US Patent 11,066,458 B2, # <a href="#"><u>17</u></a> Exhibit 17 - US Patent 11,084,865 B2, # <a href="#"><u>18</u></a> Exhibit 18 - US Patent 11,104,715 B2, # <a href="#"><u>19</u></a> Exhibit 19 - US Patent 11,174,283 B2, # <a href="#"><u>20</u></a> Exhibit 20 - US Patent 11,186,625 B2, # <a href="#"><u>21</u></a> Exhibit 21 - US Patent 11,253,572 B2, # <a href="#"><u>22</u></a> Exhibit 22 - US Patent 11,299,532 B2, # <a href="#"><u>23</u></a> Exhibit 23 - US Patent 11,306,135 B2, # <a href="#"><u>24</u></a> Exhibit 24 - US Patent 11,332,771 B2, # <a href="#"><u>25</u></a> Civil Cover Sheet, # <a href="#"><u>26</u></a> Proposed AO120 Form)(dk) (Entered: 08/03/2022)
08/03/2022	<a href="#"><u>2</u></a>	VERIFICATION OF ATTORNEY ADMISSION issued to D. Berl, E. Oberwetter, T. Fletcher, A. Trask, T. Gregory, S. Mahaffy, K. Kayali, A. Argall, A. Pan, and N. Jordan. (dk) (Entered: 08/03/2022)
08/03/2022	<a href="#"><u>3</u></a>	REPORT to USPTO on the filing or determination of an action regarding re <a href="#"><u>1</u></a> Complaint. (dk) (Entered: 08/03/2022)
08/03/2022	<a href="#"><u>5</u></a>	Corporate Disclosure Statement by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 08/03/2022)
08/04/2022	<a href="#"><u>6</u></a>	SUMMONS Returned Executed as to Mylan Pharmaceuticals Inc. served on 8/4/2022. (Pogue, David) (Entered: 08/04/2022)



08/05/2022	<a href="#">7</a>	MOTION for Hearing - <i>Requesting Expedited Status Conference</i> by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 08/05/2022)
08/08/2022	<a href="#">8</a>	<i>Application for Admission Pro Hac Vice of Arthur J. Argall III</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">9</a>	<i>Application for Admission Pro Hac Vice of Adam Pan</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">10</a>	<i>Application for Admission Pro Hac Vice of Andrew V. Trask</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">11</a>	<i>Application for Admission Pro Hac Vice of David I. Berl</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Attachment B, # <a href="#">3</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">12</a>	<i>Application for Admission Pro Hac Vice of Ellen E. Oberwetter</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">13</a>	<i>Application for Admission Pro Hac Vice of Kathryn S. Kayali</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">14</a>	<i>Application for Admission Pro Hac Vice of Nicholas W. Jordan</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">15</a>	<i>Application for Admission Pro Hac Vice of Shaun P. Mahaffy</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">16</a>	<i>Application for Admission Pro Hac Vice of Thomas S. Fletcher</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">17</a>	<i>Application for Admission Pro Hac Vice of Teagan J. Gregory</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Exhibit WWSB Receipt)(Ruby, Steven) Modified to make pending motion on 8/10/2022 (dk). (Entered: 08/08/2022)
08/08/2022	<a href="#">18</a>	NOTICE of Appearance by Gordon H. Copland on behalf of Mylan Pharmaceuticals Inc. (Copland, Gordon) (Entered: 08/08/2022)



08/10/2022	<u>19</u>	<p><b>FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING:</b></p> <p><b>***NOTICE TO ATTORNEYS*** : Pursuant to <u>Rule 7.1</u> of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at <a href="http://www.wvnd.uscourts.gov/forms.htm">http://www.wvnd.uscourts.gov/forms.htm</a></b></p> <p><b>Rule 26 Meeting to be held by 9/9/2022. Rule 26 Meeting Report due by 9/23/2022. Discovery due by 10/10/2022. Signed by Chief District Judge Thomas S Kleeh on 8/10/2022. (dk) (Entered: 08/10/2022)</b></p>
08/10/2022	<u>20</u>	Pro Hac Vice Filing fee for T. Gregory, T. Fletcher, S. Mahaffy, N. Jordan, K. Kayali, E. Oberwetter, D. Berl, A. Trask, A. Pan and A. Argall: \$2,000.00. Receipt number WVNC003489. (jb) (Entered: 08/10/2022)
08/17/2022	<u>21</u>	Application for Admission Pro Hac Vice of Petra Scamborova Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <u>1</u> Attachment WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). (Entered: 08/17/2022)
08/17/2022	<u>22</u>	Application for Admission Pro Hac Vice of Larry Coury Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <u>1</u> Attachment WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). (Entered: 08/17/2022)
08/17/2022	<u>23</u>	Application for Admission Pro Hac Vice for James Evans Other Document filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <u>1</u> Attachment WWSB Receipt)(Ruby, Steven) Modified to make a pending motion on 8/18/2022 (dk). (Entered: 08/17/2022)
08/18/2022	<u>24</u>	Filing fee for Pro Hac Vice admission of J. Evans, L. Coury and P. Scamborova in the amount of \$ 600.00. Receipt number WVNC003495. (jb) (Entered: 08/18/2022)
08/19/2022	<u>25</u>	Corporate Disclosure Statement by Mylan Pharmaceuticals Inc. identifying Corporate Parent Mylan Inc., Corporate Parent Viartis Inc. for Mylan Pharmaceuticals Inc... (O'Brien, William) (Entered: 08/19/2022)
08/19/2022	<u>26</u>	RESPONSE in Opposition re <u>7</u> MOTION for Hearing - <i>Requesting Expedited Status Conference</i> filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 08/19/2022)
08/22/2022	<u>27</u>	VERIFICATION OF ATTORNEY ADMISSION issued to Attorneys W. Rakoczy, H. Salmen, E. Hunt, N. McLaughlin, and L. Lesko. (dk) (Entered: 08/22/2022)
08/22/2022	<u>28</u>	<b>ORDER granting <u>8</u> Motion of Arthur J. Argall, III for leave to appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<u>29</u>	<b>ORDER granting <u>9</u> Motion of Adam Pan for leave to appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<u>30</u>	<b>ORDER granting <u>14</u> Motion of Nicholas W. Jordan for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<u>31</u>	<b>ORDER granting <u>13</u> Motion of Kathryn S. Kayali for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<u>32</u>	<b>ORDER granting <u>12</u> Motion of Ellen E. Oberwetter for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge</b>

		<b>Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>33</u></a>	<b>ORDER granting <a href="#"><u>11</u></a> Motion of David I. Berl for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>34</u></a>	<b>ORDER granting <a href="#"><u>10</u></a> Motion of Andrew V. Trask for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>35</u></a>	<b>ORDER granting <a href="#"><u>23</u></a> Motion of James Evans for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>36</u></a>	<b>ORDER granting <a href="#"><u>22</u></a> Motion of Larry Coury for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>37</u></a>	<b>ORDER granting <a href="#"><u>21</u></a> Motion of Petra Scamborova for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>38</u></a>	<b>ORDER granting <a href="#"><u>17</u></a> Motion of Teagan J. Gregory for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>39</u></a>	<b>ORDER granting <a href="#"><u>16</u></a> Motion of Thomas S. Fletcher for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/22/2022	<a href="#"><u>40</u></a>	<b>ORDER granting <a href="#"><u>15</u></a> Motion of Shaun P. Mahaffy for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 8/22/2022. (dk) (Entered: 08/22/2022)</b>
08/23/2022	<a href="#"><u>41</u></a>	<b>REPLY to Response to Motion re <a href="#"><u>7</u></a> MOTION for Hearing - <i>Requesting Expedited Status Conference</i> filed by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 08/23/2022)</b>
08/25/2022	<a href="#"><u>42</u></a>	<b>MOTION for Leave to Appear Pro Hac Vice (<i>Lauren M. Lesko</i>) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Proposed Order)(Copland, Gordon) (Entered: 08/25/2022)</b>
08/25/2022	<a href="#"><u>43</u></a>	<b>MOTION for Leave to Appear Pro Hac Vice (<i>William A. Rakoczy</i>) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Proposed Order)(Copland, Gordon) (Entered: 08/25/2022)</b>
08/25/2022	<a href="#"><u>44</u></a>	<b>MOTION for Leave to Appear Pro Hac Vice (<i>Neil B. McLaughlin</i>) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Proposed Order)(Copland, Gordon) (Entered: 08/25/2022)</b>
08/25/2022	<a href="#"><u>45</u></a>	<b>MOTION for Leave to Appear Pro Hac Vice (<i>Eric R. Hunt</i>) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Proposed Order)(Copland, Gordon) (Entered: 08/25/2022)</b>
08/25/2022	<a href="#"><u>46</u></a>	<b>MOTION for Leave to Appear Pro Hac Vice (<i>Heinz J. Salmen</i>) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Proposed Order)(Copland, Gordon) (Entered: 08/25/2022)</b>
08/25/2022	<a href="#"><u>47</u></a>	<b>ANSWER to <a href="#"><u>1</u></a> Complaint,,,,, , COUNTERCLAIM against Regeneron Pharmaceuticals, Inc. by Mylan Pharmaceuticals Inc..(O'Brien, William) (Entered: 08/25/2022)</b>

08/26/2022	<a href="#">48</a>	Pro Hac Vice Filing fee in the amount of \$ 1,000.00 for L. Lesko, W. Rakoczy, N. McLaughlin, E. Hunt & H. Salmen. Receipt number WVNC003501. (jb) (Entered: 08/26/2022)
08/26/2022	<a href="#">49</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Lawrence Scott Beall</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 08/26/2022)
08/26/2022	<a href="#">50</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Steven J. Birkos</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 08/26/2022)
08/26/2022	<a href="#">51</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Thomas H. Ehrich</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 08/26/2022)
08/26/2022	<a href="#">52</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Jeffrey A. Marx</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 08/26/2022)
08/29/2022	<a href="#">53</a>	Pro Hac Vice Filing fee in the amount of \$ 800.00 for attorneys J. Marx, T. Ehrich, S. Birkos and L. Beall. Receipt number WVNC003502. (jb) (Entered: 08/29/2022)
08/31/2022	<a href="#">54</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>First Set of Interrogatories to Mylan Pharmaceuticals In.c.</i> (Pogue, David) (Entered: 08/31/2022)
08/31/2022	<a href="#">55</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>First Requests for Production to Mylan Pharmaceuticals Inc..</i> (Pogue, David) (Entered: 08/31/2022)
09/05/2022	<a href="#">56</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Abraham J. Varon</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 09/05/2022)
09/06/2022	<a href="#">57</a>	<b>ORDER granting <a href="#">42</a> Motion for Leave to Appear Pro Hac Vice (<i>Lauren M. Lesko</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/06/2022	<a href="#">58</a>	<b>ORDER granting <a href="#">43</a> Motion for Leave to Appear Pro Hac Vice (<i>William A. Rakoczy</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/06/2022	<a href="#">59</a>	<b>ORDER granting <a href="#">44</a> Motion for Leave to Appear Pro Hac Vice (<i>Neil B. McLaughlin</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/06/2022	<a href="#">60</a>	<b>ORDER granting <a href="#">45</a> Motion for Leave to Appear Pro Hac Vice (<i>Eric R. Hunt</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/06/2022	<a href="#">61</a>	<b>ORDER granting <a href="#">46</a> Motion for Leave to Appear Pro Hac Vice (<i>Heinz J. Salmen</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/06/2022	<a href="#">62</a>	<b>ORDER granting <a href="#">49</a> Motion for Leave to Appear Pro Hac Vice (<i>Lawrence Scott Beall</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/06/2022	<a href="#">63</a>	<b>ORDER granting <a href="#">50</a> Motion for Leave to Appear Pro Hac Vice (<i>Steven J. Birkos</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>



09/06/2022	<a href="#">64</a>	<b>ORDER granting <a href="#">51</a> Motion for Leave to Appear Pro Hac Vice (<i>Thomas H. Ehrich</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/06/2022	<a href="#">65</a>	<b>ORDER granting <a href="#">52</a> Motion for Leave to Appear Pro Hac Vice (<i>Jeffrey A. Marx</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/6/2022. (jb) (Entered: 09/06/2022)</b>
09/07/2022	<a href="#">66</a>	PHV Filing fee for A. Varon in the amount of \$ 200.00. Receipt number WVNC03508. (jb) (Entered: 09/07/2022)
09/13/2022	<a href="#">67</a>	<b>ORDER granting <a href="#">56</a> Motion of Abraham J. Varon for Leave to Appear Pro Hac Vice on behalf of Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/13/2022. (dk) (Entered: 09/13/2022)</b>
09/13/2022	<a href="#">68</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Katie A. Boda</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 09/13/2022)
09/14/2022	<a href="#">69</a>	Pro Hac Vice Filing fee: \$ 200.00, receipt number WVNC003515 for Attorney K. Boda. (jmm) (Entered: 09/14/2022)
09/15/2022	<a href="#">70</a>	<i>Regeneron Pharmaceuticals Inc.</i> 's ANSWER to <a href="#">47</a> Answer to Complaint, Counterclaim by Regeneron Pharmaceuticals, Inc..(Ruby, Steven) (Entered: 09/15/2022)
09/16/2022	<a href="#">71</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>Regeneron's Second Requests for Production of Documents and things to Mylan Pharmaceuticals Inc.</i> (Ruby, Steven) (Entered: 09/16/2022)
09/20/2022	<a href="#">72</a>	<b>ORDER granting <a href="#">68</a> Motion of Katie A. Body for Leave to Appear Pro Hac Vice on behalf of Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 9/20/2022. (dk) (Entered: 09/20/2022)</b>
09/20/2022	<a href="#">73</a>	<b>ORDER SCHEDULING STATUS CONFERENCE for 9/28/2022 02:30 PM, via Zoom videoconferencing, before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 9/20/2022. (dk) (Entered: 09/20/2022)</b>
09/20/2022	<a href="#">74</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Plaintiff's Rule 26(a) Initial Disclosures.</i> (Ruby, Steven) (Entered: 09/20/2022)
09/23/2022	<a href="#">75</a>	REPORT of Rule 26(f) Planning Meeting. (Attachments: # <a href="#">1</a> Exhibit Exhibit A, # <a href="#">2</a> Exhibit Exhibit B)(Ruby, Steven) (Entered: 09/23/2022)
09/28/2022	<a href="#">76</a>	MINUTE ENTRY:  <b><u>***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY.</u></b>  Proceedings held before Chief District Judge Thomas S Kleeh. Status Conference held on 9/28/2022. (Court Reporter Rachel Kocher) (dk) (Entered: 09/28/2022)
09/29/2022	<a href="#">77</a>	Other Document <i>Defendant Mylan Pharmaceuticals Inc.s Post-Hearing Supplement</i> filed by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 09/29/2022)
09/29/2022	<a href="#">78</a>	RESPONSE by Regeneron Pharmaceuticals, Inc. to <a href="#">77</a> Other Document. (Attachments: # <a href="#">1</a> Proposed Order Proposed Scheduling Order)(Ruby, Steven) (Entered: 09/29/2022)
10/03/2022	<a href="#">79</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>MYLAN PARMACEUTICALS INC.S ANSWERS AND OBJECTIONS TO REGENERONS FIRST SET OF INTERROGATORIES (NOS. 1-2).</i> (Copland, Gordon) (Entered: 10/03/2022)

10/03/2022	<a href="#"><u>80</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>MYLAN PHARMACEUTICALS INC.'S RESPONSES AND OBJECTIONS TO PLAINTIFFS FIRST SET REQUESTS FOR PRODUCTION OF DOCUMENTS AND THINGS (NOS. 1-6).</i> (Copland, Gordon) (Entered: 10/03/2022)
10/06/2022	<a href="#"><u>81</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(First Requests for the Production of Documents and Things to Regeneron (Nos. 1-120)).</i> (O'Brien, William) (Entered: 10/06/2022)
10/12/2022	<a href="#"><u>82</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Defendant's Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) on 10.10.22).</i> (O'Brien, William) (Entered: 10/12/2022)
10/12/2022	<a href="#"><u>83</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Documents produced on 10.10.22).</i> (O'Brien, William) (Entered: 10/12/2022)
10/19/2022	<a href="#"><u>84</u></a>	Other Document <i>Post-Hearing Supplement</i> filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#"><u>1</u></a> Proposed Order Updated Proposed Scheduling Order)(Ruby, Steven) (Entered: 10/19/2022)
10/20/2022	<a href="#"><u>85</u></a>	Other Document <i>Post-Hearing Supplement</i> filed by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Attachment Exhibits A & B)(O'Brien, William) (Entered: 10/20/2022)
10/20/2022	<a href="#"><u>86</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Mylan Pharmaceuticals Inc.'s Responses and Objections to Plaintiffs Second Set of Requests for the Production of Documents (Nos. 7-27).</i> (Copland, Gordon) (Entered: 10/20/2022)
10/25/2022	<a href="#"><u>87</u></a>	<b>SCHEDULING ORDER: Amended Pleadings due by 12/9/2022. Joinder of Parties due by 12/9/2022. Markman Hearing set for 1/6/2023 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Fact Discovery due by 1/18/2023. Dispositive Motions due by 4/20/2023. Proposed Pretrial Order due by 5/18/2023. Final Pretrial Conference/Settlement Conference set for 5/30/2023 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Jury Selection and Jury Trial set for 6/12/2023 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 10/25/2022. (dk) (Entered: 10/25/2022)</b>
10/28/2022	<a href="#"><u>88</u></a>	STIPULATION <i>Regarding Case Narrowing and Injunctive Relief</i> by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 10/28/2022)
11/01/2022	<a href="#"><u>89</u></a>	STIPULATION <i>and Joint Request for Entry of Proposed Protective Order</i> by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Proposed Order, # <a href="#"><u>2</u></a> Exhibit Ex. A to proposed protective order, # <a href="#"><u>3</u></a> Exhibit Ex. B to proposed protective order)(Copland, Gordon) (Entered: 11/01/2022)
11/02/2022	<a href="#"><u>90</u></a>	TRANSCRIPT of Status Conference held on September 28, 2022, before Chief Judge Thomas S. Kleeh. Court Reporter/Transcriber Rachel Kocher, RPR, Telephone number 304-344-8463. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 11/23/2022. Redacted Transcript Deadline set for 12/5/2022. Release of Transcript Restriction set for 1/31/2023. (kac) (Entered: 11/02/2022)
11/02/2022	<a href="#"><u>91</u></a>	<b>STIPULATED PROTECTIVE ORDER. Signed by Chief District Judge Thomas S Kleeh on 11/2/2022. (jb) (Entered: 11/02/2022)</b>

11/02/2022	<a href="#">92</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. (Ruby, Steven) (Entered: 11/02/2022)
11/02/2022	<a href="#">93</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Mylan Pharmaceuticals Inc.'s First Requests for the Production of Documents and Things to Regeneron (Nos. 1-120).</i> (Pogue, David) (Entered: 11/02/2022)
11/04/2022	<a href="#">94</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron's Third Requests for Production of Documents to Mylan Pharmaceuticals Inc..</i> (Pogue, David) (Entered: 11/04/2022)
11/06/2022	<a href="#">95</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Documents produced on 11.4.22).</i> (O'Brien, William) (Entered: 11/06/2022)
11/11/2022	<a href="#">96</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Defendant's Preliminary Constructions and Intrinsic Support).</i> (O'Brien, William) (Entered: 11/11/2022)
11/11/2022	<a href="#">97</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>(Plaintiff's Preliminary Constructions and Intrinsic Support).</i> (Pogue, David) (Entered: 11/11/2022)
11/14/2022	<a href="#">98</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron's First Requests for Admission to Mylan Pharmaceuticals Inc..</i> (Pogue, David) (Entered: 11/14/2022)
11/15/2022	<a href="#">99</a>	MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Attachment WWSB Receipt, # <a href="#">3</a> Proposed Order)(Ruby, Steven) (Entered: 11/15/2022)
11/15/2022	<a href="#">100</a>	MOTION for Leave to Appear Pro Hac Vice of Sean M. Douglass by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Attachment WWSB Receipt, # <a href="#">3</a> Proposed Order)(Ruby, Steven) (Entered: 11/15/2022)
11/15/2022	<a href="#">101</a>	MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> Attachment WWSB Receipt, # <a href="#">3</a> Proposed Order)(Ruby, Steven) (Entered: 11/15/2022)
11/17/2022	<a href="#">102</a>	<i>JOINT CLAIM CONSTRUCTION CHART</i> Other Document filed by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 11/17/2022)
11/23/2022	<a href="#">103</a>	NOTICE by Regeneron Pharmaceuticals, Inc. <i>of Service of Subpoena</i> (Attachments: # <a href="#">1</a> Attachment)(Ruby, Steven) (Entered: 11/23/2022)
11/23/2022	<a href="#">104</a>	NOTICE by Regeneron Pharmaceuticals, Inc. <i>of Service of Subpoena</i> (Attachments: # <a href="#">1</a> Attachment)(Ruby, Steven) (Entered: 11/23/2022)
11/23/2022	<a href="#">105</a>	NOTICE by Regeneron Pharmaceuticals, Inc. <i>of Service of Subpoena</i> (Attachments: # <a href="#">1</a> Attachment)(Ruby, Steven) (Entered: 11/23/2022)
11/23/2022	<a href="#">107</a>	MEMORANDUM <i>of Law in Support of Motion for Leave to File Under Seal</i> by Regeneron Pharmaceuticals, Inc. . (Pogue, David) (Entered: 11/23/2022)
11/23/2022	<a href="#">108</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron's Fourth Request for Production of Documents to Mylan Pharmaceuticals Inc..</i> (Pogue, David) (Entered: 11/23/2022)
11/23/2022	<a href="#">109</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron's Second Set of Interrogatories to Mylan Pharmaceuticals Inc.</i> (Pogue, David) (Entered: 11/23/2022)



11/28/2022	<a href="#">110</a>	<b>ORDER granting <a href="#">101</a> MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/28/2022. (Copy counsel of record)(jmm) (Entered: 11/28/2022)</b>
11/28/2022	<a href="#">111</a>	<b>ORDER granting <a href="#">100</a> MOTION for Leave to Appear Pro Hac Vice of Sean M. Douglass filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/28/2022. (jmm) (Entered: 11/28/2022)</b>
11/28/2022	<a href="#">112</a>	<b>ORDER granting <a href="#">99</a> MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/28/2022. (jmm) (Entered: 11/28/2022)</b>
11/29/2022	<a href="#">113</a>	MOTION for Leave to Appear Pro Hac Vice of Andrew E. Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment WWSB Receipt, # <a href="#">2</a> Proposed Order)(Ruby, Steven) (Entered: 11/29/2022)
11/29/2022	<a href="#">114</a>	MOTION for Leave to Appear Pro Hac Vice of Sven Eric Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment WWSB Receipt, # <a href="#">2</a> Proposed Order)(Ruby, Steven) (Entered: 11/29/2022)
11/29/2022	<a href="#">115</a>	MOTION for Leave to Appear Pro Hac Vice of Jacob E. Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment WWSB Receipt, # <a href="#">2</a> Proposed Order)(Ruby, Steven) (Entered: 11/29/2022)
11/29/2022	<a href="#">116</a>	MOTION for Leave to Appear Pro Hac Vice of Evan T. Leo by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment WWSB Receipt, # <a href="#">2</a> Proposed Order)(Ruby, Steven) (Entered: 11/29/2022)
11/29/2022	<a href="#">117</a>	MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment WWSB Receipt, # <a href="#">2</a> Proposed Order)(Ruby, Steven) (Entered: 11/29/2022)
11/29/2022	<a href="#">118</a>	NOTICE by Regeneron Pharmaceuticals, Inc. <i>of Service of Subpoena</i> (Attachments: # <a href="#">1</a> Attachment Subpoena)(Pogue, David) (Entered: 11/29/2022)
11/29/2022	<a href="#">120</a>	MEMORANDUM <i>of Law in Support of Motion for Leave to File Under Seal</i> by Regeneron Pharmaceuticals, Inc. . (Pogue, David) (Entered: 11/29/2022)
11/29/2022	<a href="#">121</a>	Pro Hac Vice Filing fee for M. Carroll, E. Leo, J. Hartman, E. Henningson and A. Goldsmith in the amount of \$ 1,000.00 paid. Receipt number WVNC003545. (jb) (Entered: 11/29/2022)
11/29/2022	<a href="#">123</a>	Other Document <i>Memorandum of Law in Support of Motion to file under Seal Mylan Opening Claim Construction Brief</i> filed by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 11/29/2022)
11/29/2022	<a href="#">124</a>	REDACTION <i>Regeneron's Opening Claim Construction Brief</i> by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Exhibit, # <a href="#">2</a> Exhibit, # <a href="#">3</a> Exhibit, # <a href="#">4</a> Exhibit, # <a href="#">5</a> Exhibit, # <a href="#">6</a> Exhibit, # <a href="#">7</a> Exhibit, # <a href="#">8</a> Exhibit, # <a href="#">9</a> Exhibit, # <a href="#">10</a> Exhibit, # <a href="#">11</a> Exhibit, # <a href="#">12</a> Exhibit, # <a href="#">13</a> Exhibit, # <a href="#">14</a> Exhibit, # <a href="#">15</a> Exhibit, # <a href="#">16</a> Exhibit, # <a href="#">17</a> Exhibit, # <a href="#">18</a> Exhibit, # <a href="#">19</a> Exhibit, # <a href="#">20</a> Exhibit, # <a href="#">21</a> Exhibit)(Ruby, Steven) (Entered: 11/29/2022)
11/30/2022	<a href="#">125</a>	Pro Hac Vice Filing fee for H. Bernal Anderson, S. Douglass and R. Griffin in the amount of \$600.00 paid. Receipt number WVNC003546. (jb) (Entered: 11/30/2022)
11/30/2022	<a href="#">126</a>	<b>ORDER granting <a href="#">117</a> Motion of Mary Charlotte Y. Carroll for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022)</b>

11/30/2022	<a href="#">127</a>	<b>ORDER granting <a href="#">116</a> Motion of Evan T. Leo for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022)</b>
11/30/2022	<a href="#">128</a>	<b>ORDER granting <a href="#">115</a> Motion of Jacob E. Hartman for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022)</b>
11/30/2022	<a href="#">129</a>	<b>ORDER granting <a href="#">114</a> Motion of Sven E. Henningson, III for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022)</b>
11/30/2022	<a href="#">130</a>	<b>ORDER granting <a href="#">113</a> Motion of Andrew E. Goldsmith for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 11/30/2022. (dk) (Entered: 11/30/2022)</b>
11/30/2022	<a href="#">131</a>	NOTICE by Regeneron Pharmaceuticals, Inc. of <i>Deposition of Defendant Mylan Pharmaceuticals Inc. Pursuant to Fed. R. Civ. P. 30(b)(6)</i> (Pogue, David) (Entered: 11/30/2022)
12/01/2022	<a href="#">132</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 106 ). ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/1/2022. (Emailed to Counsel) (dk) (Entered: 12/01/2022)</b>
12/01/2022	<a href="#">134</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 119 ). ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/1/2022. (Emailed to Counsel) (dk) (Entered: 12/01/2022)</b>
12/01/2022	<a href="#">136</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 122 ). ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/1/2022. (Emailed to Counsel) (dk) (Entered: 12/01/2022)</b>
12/05/2022	<a href="#">137</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the <i>Notice of Deposition of Abhijit Barve.</i> (Pogue, David) (Entered: 12/05/2022)
12/05/2022	<a href="#">138</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the <i>Notice of Deposition of Prasanna Ganapathi.</i> (Pogue, David) (Entered: 12/05/2022)
12/05/2022	<a href="#">139</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the <i>Notice of Deposition of Keri Vaughan.</i> (Pogue, David) (Entered: 12/05/2022)
12/05/2022	<a href="#">140</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendants Notice of Rule 30(b)(6) Deposition of Plaintiff Regeneron Pharmaceuticals, Inc.</i> (Copland, Gordon) (Entered: 12/05/2022)
12/06/2022	<a href="#">141</a>	MOTION for Leave to Appear Pro Hac Vice of Arunabha Bhoumik by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment WVSb Receipt, # <a href="#">2</a> Proposed Order)(Ruby, Steven) (Entered: 12/06/2022)
12/06/2022	<a href="#">142</a>	MOTION for Leave to Appear Pro Hac Vice of Adam J. Bernstein by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment WVSb Receipt, # <a href="#">2</a> Proposed Order)(Ruby, Steven) (Entered: 12/06/2022)
12/06/2022	<a href="#">143</a>	MOTION to Compel Compliance with the Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment Memorandum In Support, # <a href="#">2</a> Exhibit 1, # <a href="#">3</a> Exhibit 2, # <a href="#">4</a> Exhibit 3, # <a href="#">5</a> Exhibit 4, # <a href="#">6</a> Exhibit 5, # <a href="#">7</a> Exhibit 6, # <a href="#">8</a> Proposed Order)(Ruby, Steven) (Entered: 12/06/2022)



12/07/2022	<a href="#">144</a>	Pro Hac Vice Filing Fee for A. Bhoumik and A. Bernstein in the amount of \$400.00. Receipt number WVNC003558. (jb) Modified on 12/7/2022 to edit docket text (jb). (Entered: 12/07/2022)
12/07/2022	<a href="#">145</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron's Second Requests for Admission to Mylan Pharmaceuticals Inc.</i> (Pogue, David) (Entered: 12/07/2022)
12/08/2022	<a href="#">147</a>	<b>***VACATED PER <a href="#">148</a> ORDER*** ORDER OF REFERRAL. Pursuant to 28 U.S.C. § 636, the motion <a href="#">143</a> is REFERRED to United States Magistrate Judge Michael J. Aloï for disposition. In ruling on the motion, the Magistrate Judge is authorized to consider the record, conduct a hearing if necessary, and do all things proper to render a decision. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (Copy to MJ Aloï and Counsel) (dk) Modified on 12/8/2022 (dk). (Entered: 12/08/2022)</b>
12/08/2022	<a href="#">148</a>	<b>ORDER OF REFERRAL. For reasons appearing to the Court, its previous order of referral is VACATED (ECF No. <a href="#">147</a> ). Pursuant to 28 U.S.C. § 636, Plaintiff's motion to compel (ECF No. <a href="#">143</a> ) is REFERRED to United States Magistrate Judge James P. Mazzone for disposition. In ruling on the motion, the Magistrate Judge is authorized to consider the record, conduct a hearing if necessary, and do all things proper to render a decision. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (Copy MJ Mazzone, Counsel) (dk) (Entered: 12/08/2022)</b>
12/08/2022	<a href="#">149</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 12.2.22</i> ). (O'Brien, William) (Entered: 12/08/2022)
12/08/2022	<a href="#">150</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 12.7.22</i> ). (O'Brien, William) (Entered: 12/08/2022)
12/08/2022	<a href="#">151</a>	<b>ORDER granting <a href="#">142</a> Motion of Adam J. Bernstein for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (dk) (Entered: 12/08/2022)</b>
12/08/2022	<a href="#">152</a>	<b>ORDER granting <a href="#">141</a> Motion of Arunabha Bhoumik for Leave to Appear Pro Hac Vice on behalf of Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (dk) (Entered: 12/08/2022)</b>
12/08/2022	<a href="#">153</a>	<b>ORDER SETTING BRIEFING SCHEDULE AND ORAL ARGUMENT/EVIDENTIARY HEARING re <a href="#">143</a> MOTION to Compel Compliance with the Protective Order filed by Regeneron Pharmaceuticals, Inc. Responses due by 12/13/2022. Evidentiary Hearing set for 12/15/2022 10:00 AM in Wheeling Magistrate Judge Courtroom, 4th Floor before Magistrate Judge James P. Mazzone. Signed by Magistrate Judge James P. Mazzone on 12/8/2022. (dk) (Entered: 12/08/2022)</b>
12/08/2022	<a href="#">154</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Deanne D. Mazzochi</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 12/08/2022)
12/08/2022	<a href="#">155</a>	Pro Hac Vice Filing Fee for D. Mazzochi in the amount of \$ 200.00. Receipt number WVNC003561. (jb) (Entered: 12/08/2022)
12/08/2022	<a href="#">156</a>	<b>ORDER granting <a href="#">154</a> Motion of Deanne D. Mazzochi for Leave to Appear Pro Hac Vice on behalf of Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 12/8/2022. (dk) (Entered: 12/08/2022)</b>

12/09/2022	<a href="#">157</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 11.16.22</i> ). (Copland, Gordon) (Entered: 12/09/2022)
12/09/2022	<a href="#">158</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 12.7.22</i> ). (Copland, Gordon) (Entered: 12/09/2022)
12/09/2022	<a href="#">159</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Karen Chu</i> ). (Copland, Gordon) (Entered: 12/09/2022)
12/09/2022	<a href="#">160</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Amy Johnson</i> ). (Copland, Gordon) (Entered: 12/09/2022)
12/09/2022	<a href="#">161</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Shawn Lawrence</i> ). (Copland, Gordon) (Entered: 12/09/2022)
12/09/2022	<a href="#">162</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Andrew Tustian</i> ). (Copland, Gordon) (Entered: 12/09/2022)
12/09/2022	<a href="#">163</a>	MOTION for Leave to File <i>First Amended Answer, Defenses, and Counterclaims</i> by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Attachment First Amended Answer, Defenses, and Counterclaims)(O'Brien, William) (Entered: 12/09/2022)
12/09/2022	<a href="#">164</a>	MEMORANDUM of Law in Support of Defendant's Motion for Leave to Amend Its Answer, Defenses, and Counterclaims by Mylan Pharmaceuticals Inc. re <a href="#">163</a> MOTION for Leave to File <i>First Amended Answer, Defenses, and Counterclaims</i> . (O'Brien, William) (Entered: 12/09/2022)
12/12/2022	<a href="#">165</a>	<i>Withdrawal</i> Other Document re <a href="#">143</a> MOTION to Compel Compliance with the Protective Order filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 12/12/2022)
12/12/2022	<a href="#">166</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Third Set of Interrogatories to Mylan Pharmaceuticals Inc.. (Ruby, Steven) (Entered: 12/12/2022)
12/13/2022	<a href="#">167</a>	<b>ORDER GRANTING WITHDRAWAL OF MOTION TO COMPEL. Plaintiff's request to WITHDRAW its Motion to Compel is GRANTED. Plaintiff's Motion <a href="#">143</a> is TERMINATED. Further, the hearing currently set for December 15, 2022, is CANCELLED. Signed by Magistrate Judge James P. Mazzone on 12/13/2022. (dk)</b> (Entered: 12/13/2022)
12/13/2022	<a href="#">168</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Objections and Responses to Plaintiff's Third Set of Requests for the Production of Documents (Nos. 28-38)</i> ). (O'Brien, William) (Entered: 12/13/2022)
12/14/2022	<a href="#">169</a>	NOTICE of Appearance by John D. Pizzo on behalf of Mylan Pharmaceuticals Inc. (Pizzo, John) (Entered: 12/14/2022)
12/14/2022	<a href="#">170</a>	NOTICE of Appearance by Garrett Matthew Spiker on behalf of Mylan Pharmaceuticals Inc. (Spiker, Garrett) (Entered: 12/14/2022)
12/14/2022	<a href="#">171</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Wayne Talton. (Pogue, David) (Entered: 12/14/2022)
12/14/2022	<a href="#">172</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for the Notice of Deposition of Ash Patel. (Pogue, David) (Entered: 12/14/2022)
12/16/2022	<a href="#">175</a>	MOTION for Judgment on the Pleadings <i>as to Defendant's Inequitable Conduct Defenses and Counterclaims</i> by Regeneron Pharmaceuticals, Inc.. Responses due by 12/30/2022 (Attachments: # <a href="#">1</a> Exhibit A, # <a href="#">2</a> Exhibit B, # <a href="#">3</a> Exhibit C, # <a href="#">4</a> Exhibit D)(Ruby, Steven) (Entered: 12/16/2022)

12/16/2022	<a href="#">176</a>	Memorandum in Support re <a href="#">175</a> MOTION for Judgment on the Pleadings <i>as to Defendant's Inequitable Conduct Defenses and Counterclaims</i> filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 12/16/2022)
12/19/2022	<a href="#">177</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>First Set of Requests for Admission to Regeneron Pharmaceuticals, Inc. (Nos. 1-35)</i> ). (O'Brien, William) (Entered: 12/19/2022)
12/19/2022	<a href="#">178</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)</i> ). (O'Brien, William) (Entered: 12/19/2022)
12/19/2022	<a href="#">179</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>First Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 1-17)</i> ). (O'Brien, William) (Entered: 12/19/2022)
12/19/2022	<a href="#">180</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Second Requests for the Production of Documents and Things to Regeneron (Nos. 121-155)</i> ). (O'Brien, William) (Entered: 12/19/2022)
12/19/2022	<a href="#">181</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Responses and Objections to Plaintiff's First Requests for Admission (Nos. 1-21)</i> ). (O'Brien, William) (Entered: 12/19/2022)
12/19/2022	<a href="#">182</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron Pharmaceuticals, Inc.'s Fourth Set of Interrogatories to Mylan Pharmaceuticals Inc..</i> (Pogue, David) (Entered: 12/19/2022)
12/20/2022	<a href="#">183</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Second Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 18-24)</i> ). (O'Brien, William) (Entered: 12/20/2022)
12/20/2022	<a href="#">184</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Third Requests for the Production of Documents and Things to Regeneron (Nos. 156-161)</i> ). (O'Brien, William) (Entered: 12/20/2022)
12/20/2022	<a href="#">185</a>	<b>ORDER granting 173 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/20/2022. (Emailed to Counsel) (dk) (Entered: 12/20/2022)</b>
12/20/2022	<a href="#">186</a>	<b>ORDER granting 174 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 12/20/2022. (Emailed to Counsel) (dk) (Entered: 12/20/2022)</b>
12/20/2022	<a href="#">187</a>	DEFENDANT MYLAN PHARMACEUTICALS INC.'S RESPONSIVE CLAIM CONSTRUCTION BRIEF filed by Mylan Pharmaceuticals Inc. (Attachments: # <a href="#">1</a> Exhibit 65, # <a href="#">2</a> Exhibit 66, # <a href="#">3</a> Exhibit 67, # <a href="#">4</a> Exhibit 68, # <a href="#">5</a> Exhibit 69, # <a href="#">6</a> Exhibit 70, # <a href="#">7</a> Exhibit 71, # <a href="#">8</a> Exhibit 72, # <a href="#">9</a> Exhibit 73, # <a href="#">10</a> Exhibit 74, # <a href="#">11</a> Exhibit 75, # <a href="#">12</a> Exhibit 76) (Filed under seal per <a href="#">185</a> Order) (dk) (Entered: 12/20/2022)
12/20/2022	<a href="#">188</a>	REGENERON'S RESPONSIVE CLAIM CONSTRUCTION BRIEF filed by Regeneron Pharmaceuticals, Inc. (Attachments: # <a href="#">1</a> Exhibit 22, # <a href="#">2</a> Exhibit 23, # <a href="#">3</a> Exhibit 24, # <a href="#">4</a> Exhibit 25, # <a href="#">5</a> Exhibit 26, # <a href="#">6</a> Exhibit 27, # <a href="#">7</a> Exhibit 28, # <a href="#">8</a> Exhibit 29, # <a href="#">9</a> Exhibit 30, # <a href="#">10</a> Exhibit 31, # <a href="#">11</a> Exhibit 32, # <a href="#">12</a> Exhibit 33, # <a href="#">13</a> Exhibit 34, # <a href="#">14</a> Exhibit 35, # <a href="#">15</a> Exhibit 36, # <a href="#">16</a> Exhibit 37, # <a href="#">17</a> Exhibit 38, # <a href="#">18</a> Exhibit 39, # <a href="#">19</a> Exhibit 40, # <a href="#">20</a> Exhibit 41, # <a href="#">21</a> Exhibit 42, # <a href="#">22</a> Exhibit 43, # <a href="#">23</a> Exhibit 44, # <a href="#">24</a> Exhibit 45) (Filed under seal per <a href="#">186</a> Order) (dk) (Entered: 12/20/2022)



12/21/2022	<a href="#">189</a>	MOTION for Extension of Time to File Response/Reply as to <a href="#">175</a> MOTION for Judgment on the Pleadings <i>as to Defendant's Inequitable Conduct Defenses and Counterclaims</i> by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order) (O'Brien, William) (Entered: 12/21/2022)
12/22/2022	<a href="#">190</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Service of Subpoena</i> . (Pogue, David) (Entered: 12/22/2022)
12/22/2022	<a href="#">191</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>Notice of Service of Subpoena</i> . (Pogue, David) (Entered: 12/22/2022)
12/22/2022	<a href="#">192</a>	MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Exhibit WWSB Receipt, # <a href="#">2</a> Proposed Order) (Ruby, Steven) (Entered: 12/22/2022)
12/22/2022	<a href="#">193</a>	Pro Hac Vice Filing Fee for G. Knofczynski in the amount of \$ 200.00 paid. Receipt Number WVNC003568. (jb) (Entered: 12/22/2022)
12/22/2022	<a href="#">194</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Alois Jungbauer</i> . (Pogue, David) (Entered: 12/22/2022)
12/22/2022	<a href="#">195</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Gregory MacMichael</i> . (Pogue, David) (Entered: 12/22/2022)
12/22/2022	<a href="#">196</a>	RESPONSE to Motion re <a href="#">189</a> MOTION for Extension of Time to File Response/Reply as to <a href="#">175</a> MOTION for Judgment on the Pleadings <i>as to Defendant's Inequitable Conduct Defenses and Counterclaims</i> filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 12/22/2022)
12/27/2022	<a href="#">197</a>	<b>ORDER granting <a href="#">192</a> Motion for Leave to Appear Pro Hac Vice of Grace W. Knofczynski</b> filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 12/27/2022. (jb) (Entered: 12/27/2022)
12/28/2022	<a href="#">198</a>	<b>ORDER granting <a href="#">189</a> Mylan Pharmaceuticals Inc.'s Motion for Extension of Time to File Response to Plaintiff's <a href="#">175</a> Motion for Judgment on the Pleadings. Mylan's response is due by 1/13/2023. Signed by Chief District Judge Thomas S Kleeh on 12/28/2022. (jb)</b> (Entered: 12/28/2022)
12/28/2022	<a href="#">199</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Plaintiff's First Supplemental Rule 26(a) Initial Disclosures</i> . (Pogue, David) (Entered: 12/28/2022)
12/28/2022	<a href="#">200</a>	NOTICE of Appearance by Raymond S Franks, II on behalf of Regeneron Pharmaceuticals, Inc. (Franks, Raymond) (Entered: 12/28/2022)
12/29/2022	<a href="#">201</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Amended Notice of Deposition of Prasanna Ganapathi</i> . (Pogue, David) (Entered: 12/29/2022)
12/30/2022	<a href="#">202</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Hana Chang</i> . (Pogue, David) (Entered: 12/30/2022)
12/30/2022	<a href="#">203</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Notice of Deposition of Karl Bozicevic)</i> . (O'Brien, William) (Entered: 12/30/2022)
12/30/2022	<a href="#">204</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Subpoena to Bozicevic, Field &amp; Francis LLP)</i> . (O'Brien, William) (Entered: 12/30/2022)
12/30/2022	<a href="#">205</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Answers and Objections to Regeneron's Second Set of Interrogatories (Nos. 3-4))</i> . (O'Brien, William) (Entered: 12/30/2022)

12/30/2022	<a href="#">206</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Responses and Objections to Plaintiff's Fourth Request for Production of Documents (Nos. 39-45)</i> ). (O'Brien, William) (Entered: 12/30/2022)
12/30/2022	<a href="#">207</a>	MOTION for Leave to Appear Pro Hac Vice ( <i>Jake R. Ritthamel</i> ) by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(O'Brien, William) (Entered: 12/30/2022)
01/02/2023	<a href="#">208</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Rajesh Nachankar</i> . (Pogue, David) (Entered: 01/02/2023)
01/03/2023	<a href="#">209</a>	<b>ORDER. For reasons appearing to the Court, the Markman hearing previously scheduled for January 6, 2023, is CONTINUED until January 24, 2023, 11:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 1/3/2023. (dk)</b> (Entered: 01/03/2023)
01/03/2023	<a href="#">210</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Amended Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)</i> ). (O'Brien, William) (Entered: 01/03/2023)
01/04/2023	<a href="#">211</a>	Pro Hac Vice Filing Fee for J. Ritthamel in the amount of \$200.00. Receipt Number WVNC003571. (jb) (Entered: 01/04/2023)
01/05/2023	<a href="#">212</a>	<b>ORDER granting <a href="#">207</a> Motion for Leave to Appear Pro Hac Vice of (<i>Jake R. Ritthamel</i>) filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 1/05/2023. (jb)</b> (Entered: 01/05/2023)
01/05/2023	<a href="#">213</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Sai Patil</i> . (Pogue, David) (Entered: 01/05/2023)
01/05/2023	<a href="#">214</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Parag Goyal</i> . (Pogue, David) (Entered: 01/05/2023)
01/05/2023	<a href="#">215</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Uwe Niesner</i> . (Pogue, David) (Entered: 01/05/2023)
01/06/2023	<a href="#">216</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Amended Notice of Deposition of Hana Chang</i> . (Pogue, David) (Entered: 01/06/2023)
01/06/2023	<a href="#">217</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Abby Cahn</i> . (Copland, Gordon) (Entered: 01/06/2023)
01/06/2023	<a href="#">218</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of George D. Yancopoulos</i> . (Copland, Gordon) (Entered: 01/06/2023)
01/06/2023	<a href="#">219</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Ken Graham</i> . (Copland, Gordon) (Entered: 01/06/2023)
01/06/2023	<a href="#">220</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Eric Furfine</i> . (Copland, Gordon) (Entered: 01/06/2023)
01/06/2023	<a href="#">221</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Eric Furfine</i> . (Copland, Gordon) (Entered: 01/06/2023)

01/06/2023	<a href="#">222</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Frank Cottingham.</i> (Copland, Gordon) (Entered: 01/06/2023)
01/06/2023	<a href="#">223</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals Inc.s Notice of Deposition of Jennifer Colyer.</i> (Copland, Gordon) (Entered: 01/06/2023)
01/11/2023	<a href="#">224</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>documents bearing Bates numbers MYL-AFL-BLA1081206 through MYL-AFL-BLA1081258.</i> (Copland, Gordon) (Entered: 01/11/2023)
01/11/2023	<a href="#">225</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>attachments to the documents bearing Bates Numbers MYL-AFL0018104, MYL-AFL0018949, MYL-AFL0045092, MYL-AFL0081201, MYL-AFL0082770, MYL-AFL0082773 and MYL-AFL0082800.</i> (Copland, Gordon) (Entered: 01/11/2023)
01/12/2023	<a href="#">227</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 226 ). Signed by Chief District Judge Thomas S Kleeh on 1/12/2023. (Emailed to Counsel) (dk)</b> (Entered: 01/12/2023)
01/12/2023	<a href="#">229</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Second Amended Notice of Deposition of Hana Chang.</i> (Pogue, David) (Entered: 01/12/2023)
01/13/2023	<a href="#">230</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Plaintiff's Second Supplemental Rule 26(a) Initial Disclosures.</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">231</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 10,888,601.</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">232</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 11,084,865.</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">233</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 11,104,715.</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">234</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Final Infringement Contentions of Plaintiff Regeneron Pharmaceuticals, Inc. for U.S. Patent No. 11,253,572.</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">235</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Mylan Pharmaceuticals Inc.'s Second Requests for the Production of Documents and Things (Nos. 121-155).</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">236</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron Pharmaceuticals, Inc.'s Responses and Objections to Mylan Pharmaceuticals Inc.'s First Requests for Admission (Nos. 1-35).</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">237</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-17).</i> (Pogue, David) (Entered: 01/13/2023)
01/13/2023	<a href="#">238</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Responses and Objections to Regeneron's Second Requests for Admission (Nos. 22-39).</i> (O'Brien, William) (Entered: 01/13/2023)



01/13/2023	<a href="#">239</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 1.9.23</i> ). (O'Brien, William) (Entered: 01/13/2023)
01/13/2023	<a href="#">240</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 1.10.23</i> ). (O'Brien, William) (Entered: 01/13/2023)
01/13/2023	<a href="#">241</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 1.11.23</i> ). (O'Brien, William) (Entered: 01/13/2023)
01/13/2023	<a href="#">242</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Second Amended Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)</i> ). (O'Brien, William) (Entered: 01/13/2023)
01/13/2023	<a href="#">243</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Answers and Objections to Regeneron's Third Set of Interrogatories (No. 5)</i> ). (O'Brien, William) (Entered: 01/13/2023)
01/13/2023	<a href="#">244</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 1.12.23</i> ). (O'Brien, William) (Entered: 01/13/2023)
01/13/2023	<a href="#">245</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Invalidity Contentions Regarding U.S. Patent Nos. 10,888,601, 11,084,865, 11,104,715, and 11,253,572</i> ). (O'Brien, William) (Entered: 01/13/2023)
01/17/2023	<a href="#">247</a>	NOTICE of Appearance by Stephene Raychel Gandee on behalf of Mylan Pharmaceuticals Inc. (Gandee, Stephene) (Entered: 01/17/2023)
01/17/2023	<a href="#">248</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Hanne Bak</i> ). (O'Brien, William) (Entered: 01/17/2023)
01/17/2023	<a href="#">249</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 1.16.23</i> ). (O'Brien, William) (Entered: 01/17/2023)
01/17/2023	<a href="#">250</a>	MOTION for Extension of Time to File Response/Reply <i>in Support of Plaintiff's Motion for Judgment on the Pleadings</i> by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(Pogue, David) (Entered: 01/17/2023)
01/17/2023	<a href="#">251</a>	<b>ORDER granting 246 Motion to Seal ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 1/17/2023. (Emailed to counsel) (dk)</b> (Entered: 01/17/2023)
01/17/2023	<a href="#">252</a>	MYLAN'S RESPONSE IN OPPOSITION TO REGENERON'S MOTION FOR JUDGMENT ON THE PLEADINGS AS TO MYLAN'S INEQUITABLE CONDUCT DEFENSES AND COUNTERCLAIMS. (Attachments: # <a href="#">1</a> Exhibit 1, # <a href="#">2</a> Exhibit 2, # <a href="#">3</a> Exhibit 3, # <a href="#">4</a> Exhibit 4, # <a href="#">5</a> Exhibit 5, # <a href="#">6</a> Exhibit 6, # <a href="#">7</a> Exhibit 7, # <a href="#">8</a> Exhibit 8, # <a href="#">9</a> Exhibit 9, # <a href="#">10</a> Exhibit 10, # <a href="#">11</a> Exhibit 11, # <a href="#">12</a> Exhibit 12, # <a href="#">13</a> Exhibit 13, # <a href="#">14</a> Exhibit 14, # <a href="#">15</a> Exhibit 15, # <a href="#">16</a> Exhibit 16, # <a href="#">17</a> Exhibit 17, # <a href="#">18</a> Exhibit 18, # <a href="#">19</a> Exhibit 19, # <a href="#">20</a> Exhibit 20, # <a href="#">21</a> Exhibit 21, # <a href="#">22</a> Exhibit 22) (Filed under seal per <a href="#">251</a> Order) (dk) (Entered: 01/17/2023)
01/17/2023	<a href="#">253</a>	<b>ORDER. ORDERS that Regeneron's Reply in Support of Plaintiff's Motion for Judgment on the Pleadings shall be filed on or before January 27, 2023. Signed by Chief District Judge Thomas S Kleeh on 1/17/2023. (dk)</b> (Entered: 01/17/2023)
01/17/2023	<a href="#">254</a>	NOTICE by Mylan Pharmaceuticals Inc. <i>NOTICE OF SUPPLEMENTAL AUTHORITY REGARDING CLAIM CONSTRUCTION</i> (Attachments: # <a href="#">1</a> Attachment PTAB institution decision 681 Patent, # <a href="#">2</a> Attachment PTAB institution decision 601 Patent, # <a href="#">3</a> Attachment PTAB final decision 338 Patent)(Copland, Gordon) (Entered: 01/17/2023)

01/18/2023	<a href="#">255</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 1.17.23</i> ). (O'Brien, William) (Entered: 01/18/2023)
01/18/2023	<a href="#">256</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant's Second Set of Interrogatories (Nos. 18-24)</i> . (Pogue, David) (Entered: 01/18/2023)
01/18/2023	<a href="#">257</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Mylan Pharmaceuticals Inc.'s Third Requests for Production of Documents and Things (Nos. 156-161)</i> . (Pogue, David) (Entered: 01/18/2023)
01/18/2023	<a href="#">258</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Amended Notice of Deposition of Abhijit Barve</i> . (Pogue, David) (Entered: 01/18/2023)
01/18/2023	<a href="#">259</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Notice of Deposition of Rebecca Rinker</i> . (Pogue, David) (Entered: 01/18/2023)
01/20/2023	<a href="#">260</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Answers and Objections to Regeneron's Fourth Set of Interrogatories (Nos. 6-14)</i> ). (O'Brien, William) (Entered: 01/20/2023)
01/23/2023	<a href="#">262</a>	RESPONSE by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Exhibit 1)(Ruby, Steven) (Entered: 01/23/2023)
01/23/2023	<a href="#">263</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF. NO. 261 ). ***SEALED***</b> Signed by Chief District Judge Thomas S Kleeh on 1/23/2023. (Emailed to Counsel) (dk) (Entered: 01/23/2023)
01/23/2023	<a href="#">264</a>	<b>*** SEALED *** DEFENDANT'S MOTION TO STRIKE PLAINTIFF'S UNAUTHORIZED REPLY BRIEF (ECF. NO. 228 ) ON CLAIM CONSTRUCTION ISSUES OR, ALTERNATIVELY, FOR LEAVE TO FILE RESPONSE</b> by Mylan Pharmaceuticals Inc. (Attachments: # <a href="#">1</a> Defendant's Alternative Submission, # <a href="#">2</a> Exhibit D, # <a href="#">3</a> Exhibit E, # <a href="#">4</a> Exhibit F, # <a href="#">5</a> Exhibit G, # <a href="#">6</a> Exhibit H) (Filed under seal per <a href="#">263</a> Order. (dk) (Entered: 01/23/2023)
01/23/2023	<a href="#">265</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 1.20.23</i> ). (O'Brien, William) (Entered: 01/23/2023)
01/24/2023	<a href="#">266</a>	MINUTE ENTRY:  <b><u>***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY</u></b>  Proceedings held before Chief District Judge Thomas S Kleeh. Markman Hearing held on 1/24/2023. (Court Reporter Cindy Knecht) (dk) (Entered: 01/24/2023)
01/24/2023	<a href="#">267</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for Second Amended Notice of Deposition of Abhijit Barve</i> . (Pogue, David) (Entered: 01/24/2023)
01/24/2023	<a href="#">268</a>	CLAIM CONSTRUCTION PRESENTATION filed by Regeneron Pharmaceuticals, Inc. (dk) (Entered: 01/25/2023)
01/26/2023	<a href="#">269</a>	<b>CLAIM CONSTRUCTION SLIDES</b> ( Other Document ) filed by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Attachment)(O'Brien, William) (Entered: 01/26/2023)
01/26/2023	<a href="#">270</a>	TRANSCRIPT of claim construction hearing held on 1/24/2023, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no



		such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 2/16/2023. Redacted Transcript Deadline set for 2/27/2023. Release of Transcript Restriction set for 4/26/2023. (ck) (Entered: 01/26/2023)
01/26/2023	<a href="#">271</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Third Amended Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)</i> ). (O'Brien, William) (Entered: 01/26/2023)
01/26/2023	<a href="#">272</a>	STIPULATION and Request for Entry of Agreed Supplemental Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(Ruby, Steven) (Entered: 01/26/2023)
01/27/2023	<a href="#">273</a>	TRANSCRIPT PURCHASE ORDER by Mylan Pharmaceuticals Inc. for proceedings held on 1/24/2023 before Judge Kleeh. (ck) (Entered: 01/27/2023)
01/27/2023	<a href="#">274</a>	TRANSCRIPT PURCHASE ORDER by Regeneron Pharmaceuticals, Inc. for proceedings held on 1/24/2023 before Judge Kleeh. (ck) (Entered: 01/27/2023)
01/27/2023	<a href="#">275</a>	<b>STIPULATED SUPPLEMENTAL PROTECTIVE ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/27/2023. (dk)</b> (Entered: 01/27/2023)
01/27/2023	<a href="#">276</a>	REPLY to Response to Motion re <a href="#">175</a> MOTION for Judgment on the Pleadings <i>as to Defendant's Inequitable Conduct Defenses and Counterclaims</i> filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Exhibit A)(Pogue, David) (Entered: 01/27/2023)
02/03/2023	<a href="#">277</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 2.3.23</i> ). (O'Brien, William) (Entered: 02/03/2023)
02/03/2023	<a href="#">278</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Opening Expert Report of Dr. Jay M. Stewart</i> ). (O'Brien, William) (Entered: 02/03/2023)
02/03/2023	<a href="#">279</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Opening Expert Report of Francesc Godia, Ph.D.</i> ). (O'Brien, William) (Entered: 02/03/2023)
02/03/2023	<a href="#">280</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Opening Expert Report of Dr. Thomas A. Albini</i> ). (O'Brien, William) (Entered: 02/03/2023)
02/03/2023	<a href="#">281</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Mylans Construction of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112</i> ). (O'Brien, William) (Entered: 02/03/2023)
02/03/2023	<a href="#">282</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Regenerons Claim Construction Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112</i> ). (O'Brien, William) (Entered: 02/03/2023)
02/03/2023	<a href="#">283</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Mylans Proposed Constructions of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572</i> ). (O'Brien, William) (Entered: 02/03/2023)

02/03/2023	<a href="#">284</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Regenerons Claim Construction Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572</i> ). (O'Brien, William) (Entered: 02/03/2023)
02/03/2023	<a href="#">285</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Amended Notice of Deposition of Rebecca Rinker. (Pogue, David) (Entered: 02/03/2023)
02/03/2023	<a href="#">287</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Opening Expert Report of Bernhardt L. Trout, PH.D.. (Pogue, David) (Entered: 02/03/2023)
02/03/2023	<a href="#">288</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Opening Expert Report of Karl G. Csaky, M.D., Ph. D. Regarding Infringement of U.S. Patent Nos. 11,253,572 and 10,888,601. (Pogue, David) (Entered: 02/03/2023)
02/03/2023	<a href="#">289</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Opening Expert Report and Declaration of Dr. Franklin Swartzwelder Regarding Mylan's Infringement of U.S. Patent No. 11,104,715. (Pogue, David) (Entered: 02/03/2023)
02/06/2023	<a href="#">290</a>	CORRECTED Other Document re <a href="#">278</a> Certificate of Service ( <i>Opening Expert Report of Dr. Jay M. Stewart</i> ) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023)
02/06/2023	<a href="#">291</a>	CORRECTED Other Document re <a href="#">279</a> Certificate of Service ( <i>Opening Expert Report of Francesc Godia, Ph.D.</i> ) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023)
02/06/2023	<a href="#">292</a>	CORRECTED Other Document re <a href="#">280</a> Certificate of Service ( <i>Opening Expert Report of Dr. Thomas A. Albini</i> ) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023)
02/06/2023	<a href="#">293</a>	CORRECTED Other Document re <a href="#">281</a> Certificate of Service, ( <i>Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Mylans Construction of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112</i> ) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023)
02/06/2023	<a href="#">294</a>	CORRECTED Other Document re <a href="#">282</a> Certificate of Service, ( <i>Opening Expert Report of Gregory MacMichael, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 Assuming Regenerons Claim Construction Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112</i> ) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023)
02/06/2023	<a href="#">295</a>	CORRECTED Other Document re <a href="#">283</a> Certificate of Service, ( <i>Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Mylans Proposed Constructions of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572</i> ) filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023)
02/06/2023	<a href="#">296</a>	CORRECTED Other Document re <a href="#">284</a> Certificate of Service, ( <i>Opening Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 Assuming Regenerons Claim Construction</i>

		<i>Proposal of the Claim Terms Organic Co-Solvent and Native Conformation and Regarding Claims 6, 7, 12, 13, 18, 19, 22, and 23 of U.S. Patent No. 11,253,572)</i> filed by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/06/2023)
02/06/2023	<a href="#"><u>297</u></a>	<b>ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/6/2023. Copy to counsel of record.(cmd)</b> (Entered: 02/06/2023)
02/06/2023	<a href="#"><u>298</u></a>	<b>ORDER ***SEALED***; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/6/2023. (Emailed to Counsel) (dk)</b> (Entered: 02/06/2023)
02/06/2023	<a href="#"><u>299</u></a>	<b>*** SEALED ***</b> MOTION for Presumption Under 35 U.S.C. §295 by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#"><u>1</u></a> Memorandum, # <a href="#"><u>2</u></a> Exhibit 1, # <a href="#"><u>3</u></a> Exhibit 2, # <a href="#"><u>4</u></a> Exhibit 3, # <a href="#"><u>5</u></a> Exhibit 4, # <a href="#"><u>6</u></a> Exhibit 5, # <a href="#"><u>7</u></a> Exhibit 6, # <a href="#"><u>8</u></a> Exhibit 7, # <a href="#"><u>9</u></a> Exhibit 8, # <a href="#"><u>10</u></a> Exhibit 9, # <a href="#"><u>11</u></a> Exhibit 10, # <a href="#"><u>12</u></a> Exhibit 11, # <a href="#"><u>13</u></a> Exhibit 12, # <a href="#"><u>14</u></a> Exhibit 13, # <a href="#"><u>15</u></a> Exhibit 14, # <a href="#"><u>16</u></a> Exhibit 15, # <a href="#"><u>17</u></a> Exhibit 16, # <a href="#"><u>18</u></a> Exhibit 17, # <a href="#"><u>19</u></a> Exhibit 18, # <a href="#"><u>20</u></a> Exhibit 19, # <a href="#"><u>21</u></a> Exhibit 20, # <a href="#"><u>22</u></a> Exhibit 21, # <a href="#"><u>23</u></a> Exhibit 22, # <a href="#"><u>24</u></a> Exhibit 23, # <a href="#"><u>25</u></a> Exhibit 24, # <a href="#"><u>26</u></a> Exhibit 25, # <a href="#"><u>27</u></a> Exhibit 26, # <a href="#"><u>28</u></a> Exhibit 27, # <a href="#"><u>29</u></a> Exhibit 28, # <a href="#"><u>30</u></a> Exhibit 29, # <a href="#"><u>31</u></a> Exhibit 30, # <a href="#"><u>32</u></a> Exhibit 31, # <a href="#"><u>33</u></a> Exhibit 32, # <a href="#"><u>34</u></a> Exhibit 33, # <a href="#"><u>35</u></a> Exhibit 34, # <a href="#"><u>36</u></a> Exhibit 35, # <a href="#"><u>37</u></a> Exhibit 36, # <a href="#"><u>38</u></a> Exhibit 37, # <a href="#"><u>39</u></a> Exhibit 37 part 2, # <a href="#"><u>40</u></a> Exhibit 38, # <a href="#"><u>41</u></a> Exhibit 39, # <a href="#"><u>42</u></a> Exhibit 40)(cmd) (Attachment 33 replaced on 3/2/2023 PER ORDER <a href="#"><u>325</u></a> ) (hrc). (Entered: 02/06/2023)
02/06/2023	<a href="#"><u>300</u></a>	MOTION to Substitute Exhibit 32 to Regeneron's Motion for Presumption under 35 U.S.C. 295 by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#"><u>1</u></a> Attachment Amended Exhibit 32 (to be filed under seal))(Pogue, David) (Entered: 02/06/2023)
02/10/2023	<a href="#"><u>302</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 2.8.23 bearing Bates numbers MYL-AFL-BLA1081261 through MYL-AFL-BLA1081389</i> ). (O'Brien, William) (Entered: 02/10/2023)
02/10/2023	<a href="#"><u>303</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 2.8.23 bearing Bates numbers MYL-AFL0093510 through MYL-AFL0095435</i> ). (O'Brien, William) (Entered: 02/10/2023)
02/10/2023	<a href="#"><u>304</u></a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Supplemental Expert Report of Francesc Godia, Ph.D.</i> ). (O'Brien, William) (Entered: 02/10/2023)
02/10/2023	<a href="#"><u>306</u></a>	Other Document <i>Findings of Fact and Conclusions of Law on Claim Construction Submitted By Defendant Mylan Pharmaceuticals, Inc</i> filed by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#"><u>1</u></a> Attachment proposed order on claim construction)(Copland, Gordon) (Entered: 02/10/2023)
02/17/2023	<a href="#"><u>308</u></a>	<b>ORDER granting 301 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/17/2023. (emailed counsel of record)(hrc)</b> (Entered: 02/17/2023)
02/17/2023	<a href="#"><u>310</u></a>	<b>ORDER granting 305 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/17/2023. (emailed to counsel)(hrc)</b> (Entered: 02/17/2023)
02/17/2023	<a href="#"><u>312</u></a>	<b>ORDER granting 307 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 2/17/2023. (emailed to counsel) (hrc)</b> (Entered: 02/17/2023)
02/17/2023	<a href="#"><u>315</u></a>	MOTION to Strike <i>DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS OF REGENERON PHARMACEUTICALS, INC.S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW</i> by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 02/17/2023)
02/17/2023	<a href="#"><u>316</u></a>	MEMORANDUM by Mylan Pharmaceuticals Inc. re <a href="#"><u>315</u></a> MOTION to Strike <i>DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS</i>



		OF REGENERON PHARMACEUTICALS, INC.'S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW. (Copland, Gordon) (Entered: 02/17/2023)
02/17/2023	<a href="#">317</a>	Proposed Order Mylan's Proposed Order Granting Motion to Strike re <a href="#">316</a> MEMORANDUM, by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 02/17/2023)
02/20/2023	<a href="#">318</a>	MOTION for Leave to Appear Pro Hac Vice of Rebecca A. Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment A, # <a href="#">2</a> WVSB Receipt, # <a href="#">3</a> Proposed Order)(Ruby, Steven) (Entered: 02/20/2023)
02/21/2023	<a href="#">319</a>	PHV Filing Fee for Rebecca Carter paid in the amount of \$200.00. Receipt number WVNC003608. (hrc) (Entered: 02/21/2023)
02/21/2023	<a href="#">320</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 2.17.23 bearing Bates number MYL-AFL0095436 through MYL-AFL0095448)). (O'Brien, William) (Entered: 02/21/2023)
02/22/2023	<a href="#">321</a>	<b>ORDER Granting <a href="#">318</a> Motion for Leave to Appear Pro Hac Vice of Rebecca A. Carter filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 2/22/2023. (hrc)</b> (Entered: 02/22/2023)
03/01/2023	<a href="#">323</a>	STIPULATION <i>EXTENDING TIME</i> by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 03/01/2023)
03/02/2023	<a href="#">325</a>	<b>ORDER GRANTING MOTION TO SUBSTITUTE EXHIBIT 32 [ECF NO. <a href="#">300</a> ]. Signed by Chief District Judge Thomas S Kleeh on 3/2/2023. (hrc)</b> (Entered: 03/02/2023)
03/03/2023	<a href="#">326</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Responsive Expert Report of Bernhardt L. Trout, Ph.D.</i> (Pogue, David) (Entered: 03/03/2023)
03/03/2023	<a href="#">327</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Responsive Expert Report of Dr. Karl Csaky.</i> (Pogue, David) (Entered: 03/03/2023)
03/03/2023	<a href="#">328</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Report of Richard Manning, Ph.D.</i> (Pogue, David) (Entered: 03/03/2023)
03/03/2023	<a href="#">329</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Rebuttal Expert Report of Vincent Capuano, Ph.D.</i> (Pogue, David) (Entered: 03/03/2023)
03/06/2023	<a href="#">330</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Documents produced on 3.2.23). (O'Brien, William) (Entered: 03/06/2023)
03/06/2023	<a href="#">331</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responsive Expert Report of Alan Ryder, Ph.D.). (O'Brien, William) (Entered: 03/06/2023)
03/06/2023	<a href="#">332</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Rebuttal Expert Report of Stephen R. Russell, M.D.). (O'Brien, William) (Entered: 03/06/2023)
03/06/2023	<a href="#">333</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. (Responsive Expert Report of Gregory MacMichael, Ph.D. Regarding the Non-Infringement of the Asserted Claims of U.S. Patent No. 11,084,865). (O'Brien, William) (Entered: 03/06/2023)
03/07/2023	<a href="#">334</a>	<b>***SEALED***; ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 314 ]. ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023. (hrc)</b> (Entered: 03/07/2023)
03/07/2023	<a href="#">336</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 322 ] ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023.</b>

		(hrc) (Entered: 03/07/2023)
03/07/2023	<a href="#">338</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 324 ]; ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023. (hrc) (Entered: 03/07/2023)</b>
03/08/2023	<a href="#">340</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Responsive Expert Report of Dr. Franklin Swartzwelder Regarding the Validity of U.S. Patent No. 11,104,715.</i> (Pogue, David) (Entered: 03/08/2023)
03/08/2023	<a href="#">341</a>	REPLY to Response to Motion re <a href="#">315</a> MOTION to Strike <i>DEFENDANT MYLAN PHARMACEUTICALS INC.S MOTION TO STRIKE PORTIONS OF REGENERON PHARMACEUTICALS, INC.S MARKMAN FINDINGS OF FACT AND CONCLUSIONS OF LAW</i> filed by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Exhibit Ex. A - complete emal chain, # <a href="#">2</a> Proposed Order Revised Proposed Order)(Copland, Gordon) (Entered: 03/08/2023)
03/13/2023	<a href="#">343</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Thomas A. Albini.</i> (Ruby, Steven) (Entered: 03/13/2023)
03/13/2023	<a href="#">344</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Francesc Godia.</i> (Ruby, Steven) (Entered: 03/13/2023)
03/13/2023	<a href="#">345</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Gregory MacMichael.</i> (Ruby, Steven) (Entered: 03/13/2023)
03/13/2023	<a href="#">346</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Barrett E. Rabinow.</i> (Ruby, Steven) (Entered: 03/13/2023)
03/13/2023	<a href="#">347</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Stephen R. Russell.</i> (Ruby, Steven) (Entered: 03/13/2023)
03/13/2023	<a href="#">348</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Alan Ryder.</i> (Ruby, Steven) (Entered: 03/13/2023)
03/13/2023	<a href="#">349</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Jay M. Stewart.</i> (Ruby, Steven) (Entered: 03/13/2023)
03/13/2023	<a href="#">350</a>	NOTICE by Regeneron Pharmaceuticals, Inc. <i>of Supplemental Authority Regarding Claim Construction</i> (Attachments: # <a href="#">1</a> Exhibit A)(Pogue, David) (Entered: 03/13/2023)
03/14/2023	<a href="#">351</a>	<b>ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/14/2023. (Copy to counsel of record) (jb) (Entered: 03/14/2023)</b>
03/16/2023	<a href="#">354</a>	<b>ORDER SCHEDULING STATUS CONFERENCE. Status Conference set for 3/23/2023 10:30 AM by Zoom before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 3/16/2023. (jb) (Entered: 03/16/2023)</b>
03/16/2023	<a href="#">355</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 353 ]. ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/16/2023. (hrc) (Entered: 03/16/2023)</b>
03/16/2023	<a href="#">358</a>	RESPONSE by Mylan Pharmaceuticals Inc. to <a href="#">350</a> Notice (Other). (O'Brien, William) (Entered: 03/16/2023)
03/17/2023	<a href="#">359</a>	<b>ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 357 ]; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/17/2023. (hrc) (Entered: 03/17/2023)</b>
03/17/2023	<a href="#">361</a>	<b>ORDER ***SEALED***. Copy to counsel of record. Signed by Chief District Judge</b>

		<b>Thomas S Kleeh on 3/17/2023. (hrc)</b> (Entered: 03/17/2023)
03/20/2023	<a href="#">362</a>	NOTICE/MOTION by Regeneron Pharmaceuticals, Inc. of <i>Withdrawal of Motion to Exclude and Motion for Emergency Status Conference, as Moot</i> (Attachments: # <a href="#">1</a> Exhibit 1)(Ruby, Steven) Modified on 3/21/2023 to change event to a motion (kac). (Entered: 03/20/2023)
03/21/2023	<a href="#">363</a>	<b>ORDER The Court GRANTS the motion to withdraw [ECFNo. <a href="#">362</a> ]. The motion to exclude and motion for emergency statusconference is WITHDRAWN [ECF No. 352 ]. Signed by Chief District Judge Thomas S Kleeh on 3/21/2023. (Regenerated NEF after unsealing order) (hrc)</b> (Entered: 03/21/2023)
03/24/2023	<a href="#">364</a>	MOTION for Leave to File <i>SUPPLEMENTAL SUBMISSION INFORMING THE COURT OF LATER FACTUAL DEVELOPMENTS RELEVANT TO REGENERONS PENDING § 295 MOTION</i> by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Attachment Mylan Proposed Supp. Submission on Factual Developments, # <a href="#">2</a> Exhibit Ex. 1 - Decl in Support of Supplemental Submission, # <a href="#">3</a> Proposed Order Proposed order Granting Leave to file)(Copland, Gordon) (Entered: 03/24/2023)
03/27/2023	<a href="#">365</a>	MOTION To Take Expert Deposition on April 27, 2023 (Unopposed) by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(Ruby, Steven) (Entered: 03/27/2023)
03/27/2023	<a href="#">366</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 3.17.23</i> ). (O'Brien, William) (Entered: 03/27/2023)
03/27/2023	<a href="#">367</a>	<b>ORDER ALLOWING EXPERT DEPOSITION TO OCCUR ON APRIL 27, 2023. Re: <a href="#">365</a> Motion. Signed by Chief District Judge Thomas S Kleeh on 3/27/2023. (hrc)</b> (Entered: 03/27/2023)
03/28/2023	<a href="#">368</a>	<b>ORDER ***SEALED***. Signed by Magistrate Judge James P. Mazzone on 3/28/2023. (Emailed to counsel of record) (hrc)</b> (Entered: 03/28/2023)
03/29/2023	<a href="#">369</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 3.28.23</i> ). (O'Brien, William) (Entered: 03/29/2023)
03/29/2023	<a href="#">370</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Amended Notice of Deposition of Barrett E. Rabinow</i> . (Pogue, David) (Entered: 03/29/2023)
03/29/2023	<a href="#">371</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Ivan Hofmann</i> . (Pogue, David) (Entered: 03/29/2023)
03/29/2023	<a href="#">372</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Amended Notice of Deposition of Gregory MacMichael</i> . (Pogue, David) (Entered: 03/29/2023)
03/29/2023	<a href="#">373</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Amended Notice of Deposition of Francesc Godia</i> . (Pogue, David) (Entered: 03/29/2023)
03/29/2023	<a href="#">374</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Amended Notice of Deposition of Alan Ryder</i> . (Pogue, David) (Entered: 03/29/2023)
03/30/2023	<a href="#">376</a>	<b>ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 3/30/2023. (Emailed to counsel of record) (hrc)</b> (Entered: 03/30/2023)
03/30/2023	<a href="#">378</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Vincent Capuano</i> ). (O'Brien, William) (Entered: 03/30/2023)
03/30/2023	<a href="#">379</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Karl Csaky</i> ). (O'Brien, William) (Entered: 03/30/2023)



03/30/2023	<a href="#">380</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Richard Manning</i> ). (O'Brien, William) (Entered: 03/30/2023)
03/30/2023	<a href="#">381</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Franklin Swartzwelder</i> ). (O'Brien, William) (Entered: 03/30/2023)
03/30/2023	<a href="#">382</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Notice of Deposition of Bernhardt Trout</i> ). (O'Brien, William) (Entered: 03/30/2023)
03/30/2023	<a href="#">383</a>	MOTION FOR HEARING TO BE CONDUCTED VIRTUALLY by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 03/30/2023)
03/31/2023	<a href="#">384</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Reply Expert Report of Dr. Franklin Swartzwelder Regarding Mylan's Infringement of U.S. Patent No. 11,104,715</i> . (Pogue, David) (Entered: 03/31/2023)
03/31/2023	<a href="#">385</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Reply Expert Report of Dr. Karl Csaky</i> . (Pogue, David) (Entered: 03/31/2023)
03/31/2023	<a href="#">386</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Reply Expert Report of Bernhardt L. Trout, Ph.D.</i> (Pogue, David) (Entered: 03/31/2023)
03/31/2023	<a href="#">387</a>	<b>ORDER GRANTING DEFENDANT'S MOTION <a href="#">383</a> FOR HEARING TO BE CONDUCTED VIRTUALLY. Signed by Magistrate Judge James P. Mazzone on 3/31/2023. (jb)</b> (Entered: 03/31/2023)
03/31/2023	<a href="#">388</a>	NOTICE of Appearance by Ben Bryant on behalf of Regeneron Pharmaceuticals, Inc. (Bryant, Ben) (Entered: 03/31/2023)
04/03/2023	<a href="#">390</a>	<b>SEALED ORDER GRANTING 389 MOTION; ***SEALED*** Signed by Magistrate Judge James P. Mazzone on 4/3/2023. (Copy of Order emailed to counsel.) (snc)</b> (Entered: 04/03/2023)
04/04/2023	<a href="#">393</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Reply Expert Report of Dr. Jay M. Stewart</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">394</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Reply Expert Report of Dr. Thomas A. Albini</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">395</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Reply Expert Report of Francesc Godia, Ph.D.</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">396</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Reply Expert Report of Ivan T. Hofmann</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">397</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Reply Expert Report of Margaret M. Snowden</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">398</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Reply Expert Report of Gregory MacMichael Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. § 112 and Regarding the Invalidity of Claims 6, 7, 12, 13, 18, 19, 22, and 23, Of U.S. Patent No. 11,253,572 Under 35 U.S.C. § 112</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">399</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Reply Expert Report of Barrett E. Rabinow, Ph.D. Regarding the Invalidity of the Asserted Claims of U.S. Patent No. 11,084,865 Under 35 U.S.C. §§ 102/103 and Regarding Claims 6, 7, 12, 13, 18, 19, 22, And 23 of U.S. Patent No. 11,253,572</i> ). (O'Brien, William) (Entered: 04/04/2023)

04/04/2023	<a href="#">400</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Supplemental Responsive Expert Report of Gregory MacMichael, Ph.D. Regarding the Non-Infringement of Claim 18 of U.S. Patent No. 11,084,865</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">401</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 3.31.23</i> ). (O'Brien, William) (Entered: 04/04/2023)
04/04/2023	<a href="#">402</a>	Other Document <i>Defendant's Submission of Supplemental Exhibits</i> filed by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Exhibit Ex. 13, # <a href="#">2</a> Exhibit Ex. 14, # <a href="#">3</a> Exhibit Ex. 15, # <a href="#">4</a> Exhibit Ex. 16)(Copland, Gordon) (Entered: 04/04/2023)
04/05/2023	<a href="#">404</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. ( <i>Documents produced on 4.4.23</i> ). (O'Brien, William) (Entered: 04/05/2023)
04/06/2023	<a href="#">405</a>	<b>ORDER ***SEALED***; ***SEALED*** SEALED ORDER GRANTING DEFENDANT'S 360 MOTION. Signed by Magistrate Judge James P. Mazzone on 4/6/2023. (Emailed order to counsel of record.) (snc)</b> (Entered: 04/06/2023)
04/06/2023	<a href="#">406</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Amended Notice of Deposition of Stephen R. Russell</i> . (Pogue, David) (Entered: 04/06/2023)
04/06/2023	<a href="#">407</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Amended Notice of Deposition of Jay M. Stewart</i> . (Pogue, David) (Entered: 04/06/2023)
04/06/2023	<a href="#">408</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Deposition of Margaret M. Snowden</i> . (Pogue, David) (Entered: 04/06/2023)
04/06/2023	<a href="#">409</a>	<b>ORDER granting 403 Motion to Seal; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 4/6/2023. (Emailed copy of order to counsel of record.) (snc)</b> (Entered: 04/06/2023)
04/06/2023	<a href="#">411</a>	<b>ORDER denying <a href="#">315</a> 356 Motions; ***SEALED***; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 4/6/2023. (Emailed copy of order to counsel.) (snc)</b> Modified on 4/6/2023 (snc). (Entered: 04/06/2023)
04/07/2023	<a href="#">412</a>	MOTION To Modify Production Deadline by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Exhibit A, # <a href="#">2</a> Proposed Order)(Pogue, David) (Entered: 04/07/2023)
04/10/2023	<a href="#">413</a>	Memorandum in Opposition re <a href="#">412</a> MOTION To Modify Production Deadline filed by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Proposed Order)(Copland, Gordon) (Entered: 04/10/2023)
04/10/2023	<a href="#">414</a>	REPLY to Response to Motion re <a href="#">412</a> MOTION To Modify Production Deadline filed by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/10/2023)
04/10/2023	<a href="#">415</a>	Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Exhibit A, # <a href="#">2</a> Exhibit B, # <a href="#">3</a> Exhibit C, # <a href="#">4</a> Exhibit D, # <a href="#">5</a> Exhibit E)(O'Brien, William) (Entered: 04/10/2023)
04/10/2023	<a href="#">416</a>	<b>ORDER granting in part and denying in part <a href="#">412</a> Motion To Modify Production Deadline filed by Regeneron Pharmaceuticals, Inc. Signed by Magistrate Judge James P. Mazzone on 4/10/2023. (hrc)</b> (Entered: 04/10/2023)
04/11/2023	<a href="#">417</a>	MOTION for Status Conference (Unopposed) by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/11/2023)
04/11/2023	<a href="#">418</a>	<b>ORDER GRANTING UNOPPOSED MOTION <a href="#">417</a> FOR STATUS CONFERENCE. Signed by Magistrate Judge James P. Mazzone on 4/11/2023. (hrc)</b> (Entered: 04/11/2023)



04/11/2023		Set Deadlines/Hearings: MJ Status Conference set for 4/11/2023 02:30 PM in Wheeling Magistrate Judge Courtroom, 4th Floor before Magistrate Judge James P. Mazzone. (hrc) (Entered: 04/11/2023)
04/11/2023	<a href="#">419</a>	MINUTE ENTRY:  <b><u>***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY.</u></b>  Proceedings held before Magistrate Judge James P. Mazzone: Status Conference held on 4/11/2023. (Tape #WHG Mazzone 1 22 cv 61 Regeneron v Mylan 4 11 23) (ag) (Entered: 04/11/2023)
04/12/2023	<a href="#">420</a>	RESPONSE to Motion re <a href="#">415</a> Emergency MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Exhibit 1)(Ruby, Steven) (Entered: 04/12/2023)
04/12/2023	<a href="#">421</a>	<b>ORDER. The Court DIRECTED Plaintiff to produce any and all documents that it is currently able to produce by the end of the day Wednesday, April 12, 2023. The Court further DIRECTED that the balance of the documents to be produced must be produced by no later than noon on Thursday, April 13, 2023. Signed by Magistrate Judge James P. Mazzone on 4/12/2023. (hrc)</b> (Entered: 04/12/2023)
04/12/2023	<a href="#">422</a>	STIPULATION <i>Regarding Expert Discovery Following Court's April 6, 2023 Discovery Ruling</i> by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/12/2023)
04/13/2023	<a href="#">423</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Amended Notice of Deposition of Thomas A. Albini.</i> (Pogue, David) (Entered: 04/13/2023)
04/13/2023	<a href="#">424</a>	NOTICE by Regeneron Pharmaceuticals, Inc. <i>Regarding Plaintiff's Production Status</i> (Pogue, David) (Entered: 04/13/2023)
04/14/2023	<a href="#">425</a>	<b>ORDER DENYING EMERGENCY MOTION TO MODIFY SCHEDULING ORDER AND FOR EMERGENCY STATUS CONFERENCE [ECF NO. <a href="#">415</a> ]. Signed by Chief District Judge Thomas S Kleeh on 4/14/2023. (hrc)</b> (Entered: 04/14/2023)
04/14/2023	<a href="#">426</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>(Amended Notice of Deposition of Bernhardt L. Trout).</i> (O'Brien, William) (Entered: 04/14/2023)
04/19/2023	<a href="#">427</a>	<b>ORDER ON CLAIM CONSTRUCTION. Signed by Chief District Judge Thomas S Kleeh on 4/19/2022. (hrc)</b> (Entered: 04/19/2023)
04/20/2023	<a href="#">428</a>	MOTION for Summary Judgment by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment Memorandum of Points and Authorities in Support of Regeneron's Motion for Summary Judgment, # <a href="#">2</a> Exhibit 1, # <a href="#">3</a> Exhibit 2, # <a href="#">4</a> Exhibit 3, # <a href="#">5</a> Exhibit 4, # <a href="#">6</a> Exhibit 5, # <a href="#">7</a> Exhibit 6, # <a href="#">8</a> Exhibit 7, # <a href="#">9</a> Exhibit 8, # <a href="#">10</a> Exhibit 9, # <a href="#">11</a> Exhibit 10, # <a href="#">12</a> Exhibit 11, # <a href="#">13</a> Exhibit 12, # <a href="#">14</a> Exhibit 13)(Ruby, Steven) (Entered: 04/20/2023)
04/20/2023	<a href="#">429</a>	MOTION for Summary Judgment <i>Defendant Mylan Pharmaceuticals Inc.s Motion for Summary Judgment or Partial Summary Judgment on U.S. Patent Nos. 11,104,715 (Process Patent); 11,084,865 (Formulation Patent); And 10,888,601 &amp; 11,253,572 (Dosing Patents)</i> by Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 04/20/2023)
04/25/2023	<a href="#">431</a>	<b>ORDER ***SEALED***. Signed by Chief District Judge Thomas S Kleeh on 4/25/2023. (emailed to counsel of record) (hrc)</b> (Entered: 04/25/2023)

04/27/2023	<a href="#">433</a>	STIPULATION <i>Regarding Summary Judgment and Case Narrowing</i> by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 04/27/2023)
04/28/2023	<a href="#">434</a>	<b>ORDER GRANTING DEFENDANT'S MOTION FOR LEAVE TO FILE FIRST AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS [ECF NO. <a href="#">163</a> ]. Signed by Chief District Judge Thomas S Kleeh on 4/28/2023. (hrc)</b> (Entered: 04/28/2023)
04/28/2023	<a href="#">435</a>	DEFENDANT'S FIRST AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFF'S COMPLAINT <a href="#">1</a> . (hrc) (Entered: 04/28/2023)
04/28/2023	<a href="#">436</a>	<b>ORDER granting <a href="#">364</a> Motion for Leave to File SUPPLEMENTAL SUBMISSION INFORMING THE COURT OF LATER FACTUAL DEVELOPMENTS RELEVANT TO REGENERONS PENDING § 295 MOTION</b> filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 4/28/2023. (jb) (Entered: 04/28/2023)
05/02/2023	<a href="#">437</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Supplemental Report of Richard Manning, Ph.D.</i> (Pogue, David) (Entered: 05/02/2023)
05/02/2023	<a href="#">438</a>	Other Document <i>Request for Denial of Motion for Presumption Under 35 U.S.C. 295, as Moot</i> filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 05/02/2023)
05/04/2023	<a href="#">439</a>	MOTION Pursuant to Rule 56(d) to Defer and Conduct Further Discovery to Adequately Oppose Summary Judgment re <a href="#">428</a> MOTION for Summary Judgment by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Exhibit 1)(O'Brien, William) (Entered: 05/04/2023)
05/08/2023	<a href="#">442</a>	<b>ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/8/2023. (emailed to counsel of record) (hrc)</b> (Entered: 05/08/2023)
05/08/2023	<a href="#">444</a>	<b>ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/8/2023. (emailed to counsel of record) (hrc)</b> (Entered: 05/08/2023)
05/09/2023	<a href="#">446</a>	CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc. <i>Defendant Mylan Pharmaceuticals, Inc.s Notice of Supplemental Deposition of Richard Manning.</i> (Copland, Gordon) (Entered: 05/09/2023)
05/10/2023	<a href="#">447</a>	CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. <i>for the Notice of Supplemental Deposition of Ivan Hofmann.</i> (Pogue, David) (Entered: 05/10/2023)
05/11/2023	<a href="#">450</a>	MOTION in Limine (No. 2) <i>To Exclude Testimony Relating to Claimed Subject Matter That Has Been Stipulated As Invalid</i> by Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 05/11/2023)
05/11/2023	<a href="#">451</a>	MOTION in Limine (No. 7) <i>To Exclude and Preclude Testimony of Dr. Karl Csaky</i> by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Exhibit A)(O'Brien, William) (Entered: 05/11/2023)
05/11/2023	<a href="#">452</a>	MOTION in Limine (No. 8) <i>To Preclude The Use of Testimony From Mylan Expert Dr. Alan Ryder Relating to Claimed Subject Matter He Did Not Opine On</i> by Mylan Pharmaceuticals Inc.. (Attachments: # <a href="#">1</a> Exhibit A, # <a href="#">2</a> Exhibit B, # <a href="#">3</a> Exhibit C)(O'Brien, William) (Entered: 05/11/2023)
05/11/2023	<a href="#">453</a>	MOTION in Limine <i>to Exclude Inequitable Conduct Opinions of Dr. Thomas A. Albini</i> by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment Memorandum of Law in Support, # <a href="#">2</a> Exhibit 1, # <a href="#">3</a> Exhibit 2, # <a href="#">4</a> Exhibit 3, # <a href="#">5</a> Exhibit 4)(Pogue, David) (Entered: 05/11/2023)

05/12/2023	<a href="#">456</a>	<b>ORDER. Denied as Moot [ECF No. 299]. Signed by Chief District Judge Thomas S Kleeh on 5/12/2023. (hrc)</b> (Entered: 05/12/2023)
05/12/2023	<a href="#">457</a>	<b>ANSWER TO DEFENDANT MYLAN PHARMACEUTICALS INC.'S FIRST AMENDED COUNTERCLAIMS</b> Other Document re <a href="#">435</a> Answer to Counterclaim filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 05/12/2023)
05/15/2023	<a href="#">458</a>	<b>CERTIFICATE OF SERVICE</b> by Mylan Pharmaceuticals Inc. ( <i>Production of documents MYL-AFL0098838 through MYL-AFL0099910 (MYL-AFL 019)</i> ). (O'Brien, William) (Entered: 05/15/2023)
05/15/2023	<a href="#">459</a>	<b>CERTIFICATE OF SERVICE</b> by Mylan Pharmaceuticals Inc. ( <i>Production of documents MYL-AFL0099911 through MYL-AFL0099995 (MYL-AFL 020)</i> ). (O'Brien, William) (Entered: 05/15/2023)
05/15/2023	<a href="#">460</a>	<b>CERTIFICATE OF SERVICE</b> by Mylan Pharmaceuticals Inc. ( <i>Production of documents MYL-AFL0099996 through MYL-AFL0102176 (MYL-AFL 021-23)</i> ). (O'Brien, William) (Entered: 05/15/2023)
05/15/2023	<a href="#">461</a>	<b>CERTIFICATE OF SERVICE</b> by Mylan Pharmaceuticals Inc. ( <i>Notice Pursuant to 35 U.S.C. § 282</i> ). (O'Brien, William) (Entered: 05/15/2023)
05/15/2023	<a href="#">462</a>	<b>ORDER ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/15/2023. (emailed to counsel of record) (hrc)</b> (Entered: 05/15/2023)
05/15/2023	<a href="#">464</a>	<b>ORDER granting 454 Motion to Seal ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/15/2023. (Emailed to Counsel) (dk)</b> (Entered: 05/15/2023)
05/15/2023	<a href="#">465</a>	<b>ORDER; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/15/2023. (emailed to counsel of record) (hrc)</b> (Entered: 05/15/2023)
05/17/2023	<a href="#">468</a>	<b>ORDER; ***SEALED*** Signed by Chief District Judge Thomas S Kleeh on 5/17/2023. (emailed to counsel of record) (hrc)</b> (Entered: 05/17/2023)
05/18/2023	<a href="#">475</a>	<b>RESPONSE in Opposition</b> re <a href="#">439</a> MOTION Pursuant to Rule 56(d) to Defer and Conduct Further Discovery to Adequately Oppose Summary Judgment re <a href="#">428</a> MOTION for Summary Judgment filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 05/18/2023)
05/18/2023	<a href="#">481</a>	<b>Proposed Order Regarding Mylan's Motion in Limine No. 1</b> by Regeneron Pharmaceuticals, Inc. (Pogue, David) (Entered: 05/18/2023)
05/18/2023	<a href="#">483</a>	<b>MOTION to Strike New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment or in the Alternative for Leave to File a Surreply</b> by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment Surreply)(Ruby, Steven) (Entered: 05/18/2023)
05/19/2023	<a href="#">484</a>	<b>Amended MOTION to Strike New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment or In the Alternative for Leave to File a Surreply</b> by Regeneron Pharmaceuticals, Inc.. (Attachments: # <a href="#">1</a> Attachment Regeneron's Surreply to Address New Arguments Raised in Mylan's Reply in Support of its Motion for Summary Judgment, # <a href="#">2</a> Exhibit A)(Ruby, Steven) (Entered: 05/19/2023)

**PACER Service Center**

**Transaction Receipt**

05/23/2023 14:15:49			
<b>PACER Login:</b>	jack_tinney	<b>Client Code:</b>	AMGEN.000001
<b>Description:</b>	Docket Report	<b>Search Criteria:</b>	1:22-cv-00061-TSK-JPM
<b>Billable Pages:</b>	30	<b>Cost:</b>	3.00